



4F-MDMB-BICA

Report on the risk assessment of methyl 2-[[1-(4-fluorobutyl)-1*H*-indole-3-carbonyl] amino]-3,3-dimethylbutanoate (4F-MDMB-BICA) in accordance with Article 5c of Regulation (EC) No 1920/2006 (as amended)

About this series

EMCDDA Risk Assessments are publications examining the health and social risks of individual new psychoactive substances.

The Risk Assessment Report consists of an analysis of the scientific and law enforcement information available on the new psychoactive substance under scrutiny and the implications of placing it under control. It is the outcome of a meeting convened under the auspices of the EMCDDA Scientific Committee.

This process is part of a three-step procedure involving information exchange/early warning, risk assessment and decision-making in the framework of Regulation (EC) 1920/2006 (as amended by Regulation (EU) 2017/2101).

Contents

Acknowledgements.....	3
Statement regarding the United Kingdom.....	4
Foreword.....	5
EMCDDA Initial Report on methyl 2-[[1-(4-fluorobutyl)-1 <i>H</i> -indole-3-carbonyl]amino]-3,3-dimethylbutanoate (4F-MDMB-BICA)	6
Risk assessment report on a new psychoactive substance: methyl 2-[[1-(4-fluorobutyl)-1 <i>H</i> -indole-3-carbonyl]amino]-3,3-dimethylbutanoate (4F-MDMB-BICA)	7
Annex 1: Technical report on the new psychoactive substance methyl 2-[[1-(4-fluorobutyl)-1 <i>H</i> -indole-3-carbonyl]amino]-3,3-dimethylbutanoate (4F-MDMB-BICA)	25
Annex 2: Participants of the risk assessment meeting, 7 December 2020.....	67

Acknowledgements

The EMCDDA would like to thank the following for their contribution in producing this publication:

- the members of the extended Scientific Committee of the EMCDDA; the advisers to the Scientific Committee and the invited external experts who took part in the risk assessment meeting;
- the Early Warning System (EWS) correspondents of the Reitox national focal points (NFPs) and experts from their national EWS networks;
- the services within each Member State that collected the raw data for the risk assessment;
- Europol, the Europol national units (ENUs) and Europol Project Synergy;
- the national competent authorities responsible for human and veterinary medicinal products in the Member States, Norway, Iceland and Liechtenstein;
- the European Medicines Agency (EMA);
- the European Chemicals Agency (ECHA), the European Centre for Disease Prevention and Control (ECDC), the European Food Safety Authority (EFSA) and the European Commission;
- the World Health Organization;
- Dr Simon Brandt, School of Pharmacy and Biomolecular Sciences, Liverpool John Moores University, Liverpool;
- Public Health Agency of Sweden (PHA) and National Board of Forensic Medicine (NBFM), Sweden;
- Prof. Christophe P Stove, Ghent University, Belgium, and Dr Samuel D Banister, University of Sydney, Australia;
- Dr Craig McKenzie, Leverhulme Research Centre for Forensic Science (LRCFS), University of Dundee;
- Prof. Volker Auwärter, University of Freiburg, Germany;
- Dr István Ujváry, hon. associate professor, Budapest University of Technology and Economics; hon. associate professor, University of Szeged; iKem BT, Budapest.

We also wish to thank EMCDDA colleagues Katarzyna Natoniewska and the Communication Unit for their work in producing this publication.

Project team: Anabela Almeida, Rachel Christie, Paulete Duque, Michael Evans-Brown, Ana Gallegos, Rita Jorge, Joanna De Moraes, Gregorio Planchuelo and Roumen Sedefov.

Project leaders: Michael Evans-Brown, Ana Gallegos and Roumen Sedefov.

Statement regarding the United Kingdom

This report covers a reference period from January to November 2020. The United Kingdom left the European Union as of 1 February 2020. However, during the transitional period, the United Kingdom continues to participate in the European Union Early Warning System on new psychoactive substances. Unless stated otherwise, for the purpose of this report, the term 'Member States' shall include the United Kingdom.

Foreword

This publication presents the data and findings of the risk assessment on 4F-MDMB-BICA (methyl 2-[[1-(4-fluorobutyl)-1*H*-indole-3-carbonyl]amino]-3,3-dimethylbutanoate), carried out by the extended Scientific Committee of the EMCDDA on 7 December 2020.

The Risk Assessment Report, which was submitted to the European Commission on 9 December 2020, examines the health and social risks of the drug, information on international trafficking and the involvement of organised crime, as well as a consideration of the potential implications of subjecting the drug to control measures.

On the basis of the Risk Assessment Report, the Commission adopted delegated act in order to add 4F-MDMB-BICA in to the definition of a drug in the Annex of the Council Framework Decision 2004/757/JHA (as amended by Directive (EU) 2017/2103). This decision was adopted in the final stage of the three-step process — early warning, risk assessment and control of new psychoactive substances — established by Regulation (EC) 1920/2006 (as amended) and Council Framework Decision 2004/757/JHA (as amended).

Regulation (EC) 1920/2006 (as amended) and Council Framework Decision 2004/757/JHA (as amended) allow the EU institutions and Member States to act on all new and potentially threatening narcotic and psychotropic drugs which appear on the European drug scene, with the EMCDDA and Europol, in collaboration with their respective networks playing a central role in the early detection of such substances as well as the harms caused by their use — information that underpins risk assessment, and, ultimately, decision-making.

In this respect we would like to acknowledge the essential role played by the respective networks in the Member States — the Reitox national focal points — in collecting and providing national data. We would also like to acknowledge the role of Europol and Europol National Units, the European Medicines Agency (EMA) and the national competent authorities responsible for medicinal products, the European Chemicals Agency (ECHA), the European Centre for Disease Prevention and Control (ECDC) and the European Food Safety Authority (EFSA) that provided valuable input to the report, thus guaranteeing its truly multidisciplinary nature.

Finally, we would like to thank all the participants in the risk assessment process for the high quality of work carried out. This procedure occurred under challenging circumstances, amidst the coronavirus (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The resulting report is a valuable contribution at European level, and provides clear support to political decision-making.

Professor Dr Catherine Comiskey
Chair, Scientific Committee of the EMCDDA

Alexis Goosdeel
Director, EMCDDA

EMCDDA Initial Report on methyl 2-[[1-(4-fluorobutyl)-1*H*-indole-3-carbonyl]amino]-3,3-dimethylbutanoate (4F-MDMB-BICA)

On 2 September 2020, the EMCDDA assessed the existing information on methyl 2-[[1-(4-fluorobutyl)-1*H*-indole-3-carbonyl]amino]-3,3-dimethylbutanoate (commonly known as 4F-MDMB-BICA), based on the following criteria: (1) reports of health problems; (2) reports of social problems; (3) reports of seized material; (4) pharmacological and toxicological properties and analogy with better-studied substances; and, (5) potential for further spread.

The EMCDDA concluded that the assessment gave rise to concerns that 4F-MDMB-BICA may pose health or social risks at Union level, and, consequently, determined that an initial report should be produced.

On 14 October 2020, the EMCDDA submitted to the Commission and Member States an initial report on the new psychoactive substance 4F-MDMB-BICA, in accordance with Article 5b of the Regulation (EC) 1920/2006 (as amended). The report concluded that the health and social risks, caused by the use of, the manufacture of, and traffic in 4F-MDMB-BICA, as well as the involvement of organised crime and possible consequences of control measures, could be thoroughly assessed through a risk assessment procedure as foreseen by Article 5c of the Regulation (EC) 1920/2006 (as amended).

The full text of the Initial Report can be found at:

https://www.emcdda.europa.eu/publications/initial-reports/4f-mdmb-bica_en

Risk assessment report on a new psychoactive substance: methyl 2-[[1-(4-fluorobutyl)-1*H*-indole-3-carbonyl]amino]-3,3-dimethylbutanoate (4F-MDMB-BICA)

Introduction

New psychoactive substances can cause serious cross-border threats to health. In Europe, Regulation (EC) No 1920/2006 of the European Parliament and of the Council of 12 December 2006 on the European Monitoring Centre for Drugs and Drug Addiction (recast) (as amended) (hereafter the 'Regulation') and Council Framework Decision 2004/757/JHA of 25 October 2004 laying down minimum provisions on the constituent elements of criminal acts and penalties in the field of illicit drug trafficking sets up a three-step legal framework of early warning, risk assessment and control measures that allows the EU to rapidly detect, assess and respond to the public health and social risks caused by new psychoactive substances. The European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) is responsible for the first two steps in this system, namely operating the EU Early Warning System on new psychoactive substances (EWS) in close cooperation with Europol, and conducting risk assessments. The European Commission is responsible for proposing control measures. Thus, the legal framework allows the institutions of the EU and the Member States to act on all new psychoactive substances (NPS) that appear on the European drug market.

In accordance with Article 5a of the Regulation, methyl 2-[[1-(4-fluorobutyl)-1*H*-indole-3-carbonyl]amino]-3,3-dimethylbutanoate (commonly known as 4F-MDMB-BICA) was formally notified as an NPS by the EMCDDA on behalf of Belgium on 2 July 2020. The notification was based on the identification of the substance in 1.5 kilograms of white powder seized by Belgian Customs at Bierset Airport, Belgium, on 31 March 2020. The seizure originated from China and was en route to the Netherlands.

Based on the information reported to the Early Warning System, and, in accordance with Article 5a of the Regulation, on 2 September 2020, the EMCDDA assessed the existing information on 4F-MDMB-BICA. The EMCDDA concluded that the assessment gave rise to concerns that 4F-MDMB-BICA may pose health or social risks at EU level, and, consequently, determined that an initial report should be produced in accordance with Article 5b of the Regulation. The initial report was submitted to the Commission and Member States on 14 October 2020. Based on the findings of the initial report, on 28 October 2020, the Commission requested that the EMCDDA carry out a risk assessment on 4F-MDMB-BICA in accordance with Article 5c of the Regulation.

This risk assessment report presents the summary findings and the conclusion of the risk assessment carried out by the Scientific Committee of the EMCDDA on 4F-MDMB-BICA. The report is intended for policymakers and decision-makers in the institutions of the EU.

The report has been prepared and drafted in accordance with the requirements of Article 5c of the Regulation as well as the conceptual framework and the procedure set out in the EMCDDA risk assessment operating guidelines. It is written as a stand-alone document, which presents a summary of the information considered during the detailed assessment of the scientific and law enforcement information available at this time. The conclusion section of the report summarises the main issues addressed and reflects the opinions held by the members of the Scientific Committee. A list of the information resources considered by the Scientific Committee, including a detailed technical report on 4F-MDMB-BICA prepared by the EMCDDA (Annex 1), is provided below.

In accordance with Article 5c of the Regulation, the meeting to assess the risks of 4F-MDMB-BICA was convened under the auspices of the Scientific Committee of the EMCDDA with the participation of four additional experts designated by the Director of the EMCDDA, acting on the advice of the Chairperson of the Scientific Committee, chosen from a list of experts approved by the Management Board of the EMCDDA. The additional experts were from scientific fields that were either not represented or not sufficiently represented in the Scientific Committee, and whose contribution is necessary for the balanced assessment of the risks posed by 4F-MDMB-BICA. A further six experts were observers to the risk assessment: two experts from the Commission, two experts from the EMCDDA, one expert from Europol, and one expert from the European Medicines Agency (EMA). The meeting took place on 7 December 2020. Owing to the on-going response to the coronavirus (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the meeting was conducted by videoconference and hosted by the EMCDDA.

The risk assessment was carried out on the basis of information provided to the Scientific Committee by the Member States, the EMCDDA, Europol, the EMA, the European Centre for Disease Prevention and Control (ECDC), the European Chemicals Agency (ECHA) and the European Food Safety Authority (EFSA). A list of the Scientific Committee members, observers and other participants attending the risk assessment meeting is annexed to this report (Annex 2).

For the risk assessment, the Scientific Committee considered the following information resources:

- the EMCDDA technical report on methyl 2-([1-(4-fluorobutyl)-1*H*-indole-3-carbonyl]amino)-3,3-dimethylbutanoate (4F-MDMB-BICA) (Annex 1);
- the EMCDDA initial report on the new psychoactive substance methyl 2-([1-(4-fluorobutyl)-1*H*-indol-3-yl]carbonyl)amino)-3,3-dimethylbutanoate (4F-MDMB-BICA);
- open source information, including scientific articles, official reports, grey literature, Internet drug discussion forums and related websites;
- additional information provided during the course of the risk assessment meeting by the participants;

- EMCDDA operating guidelines for the risk assessment of new psychoactive substances;
- Regulation (EC) No 1920/2006 of the European Parliament and of the Council of 12 December 2006 on the European Monitoring Centre for Drugs and Drug Addiction (recast) (as amended); and
- Council Framework Decision 2004/757/JHA of 25 October 2004 laying down minimum provisions on the constituent elements of criminal acts and penalties in the field of illicit drug trafficking (as amended).

Background

Methyl 2-[[1-(4-fluorobutyl)-1*H*-indole-3-carbonyl]amino]-3,3-dimethylbutanoate (4F-MDMB-BICA) is a synthetic cannabinoid receptor agonist (synthetic cannabinoid) which does not appear to have a history in the scientific literature. However, it is structurally related to compounds of the indole-3-carboxamide class that feature pendant amino acid esters (methyl *L-tert*-leucinate) previously developed as part of pharmaceutical research.

Synthetic cannabinoids, such as 4F-MDMB-BICA, are functionally similar to Δ^9 -tetrahydrocannabinol (THC), the major psychoactive principle of cannabis. Like THC, they bind to and activate the CB₁ and CB₂ cannabinoid receptors which form part of the endocannabinoid system — a system that helps regulate a large number of physiological functions in the body such as behaviour, mood, pain, appetite, sleep, the immune system, and the cardiovascular system.

Many synthetic cannabinoids were first developed to study the endocannabinoid system as well as to explore their potential as therapeutic agents to treat a number of diseases and their symptoms (such as neurodegenerative diseases, drug dependence, pain disorders, and cancer).

Since around 2006, 'legal high' products containing synthetic cannabinoids have been sold in Europe as 'herbal smoking mixtures' and marketed as 'legal' replacements for cannabis. These products are made by dissolving the synthetic cannabinoids in solvents such as acetone or methanol and then mixing them with, or, spraying them on, plant material such as the herbs *Turnera diffusa* (Damiana) and other herbs such as *Melissa*, *Mentha* and *Thymus* species of the Lamiaceae family. Such products are generally referred to by a variety of names in Europe, including 'Spice' (1), 'herbal smoking mixtures', 'herbal incense', and 'synthetic cannabis'. They may also be mixed with tobacco. Manufacturers of smoking mixtures frequently change the synthetic cannabinoids in the products, which means that product names are not a reliable source of information regarding the actual substances that are present. More than 210 synthetic cannabinoids have been identified on the European drug market since 2008. They are the largest group of substances that are monitored by the

(1) 'Spice' was the most common brand name used for these types of products when they first appeared on the European market.

EMCDDA through the EU Early Warning System. In recent years, alongside smoking mixtures, new dosage forms, including e-liquids for vaping using electronic cigarettes, as well as paper (including blotters) impregnated with synthetic cannabinoids, have appeared on the drug market.

A number of cannabinoids are controlled under the United Nations Convention on Psychotropic Substances, 1971. These include: the major active principle of cannabis, Δ^9 -tetrahydrocannabinol ⁽²⁾ (Schedule I), dronabinol ⁽³⁾ (Schedule II) as well as an increasing number of synthetic cannabinoids, including 4F-MDMB-BINACA ⁽⁴⁾ and 5F-MDMB-PICA ⁽⁵⁾(Schedule II) that are closely related to 4F-MDMB-BICA.

4F-MDMB-BICA has been available on the drug market in Europe since at least March 2020. It is important to highlight that, as 4F-MDMB-BICA has emerged on the drug market only recently, no formal epidemiological studies have been conducted, which limits understanding of the frequency and patterns of use of the substance. Related to this, the presence of 4F-MDMB-BICA on the drug market and its involvement in serious adverse events (such as acute poisonings presenting to hospital emergency rooms and medico-legal death investigations) may be underreported because the substance is not routinely screened for in some forensic and toxicology laboratories in Europe. Therefore, the presence of 4F-MDMB-BICA on the drug market may be undetected in some areas. In addition, in some areas not all laboratories are part of national early warning systems; for this reason, the identification of 4F-MDMB-BICA may go unreported to the Reitox national focal points, and, as a result, to the EMCDDA. Finally, it is also important to note that, in some settings, the on-going COVID-19 pandemic may have reduced the capacity of early warning systems, including forensic science and toxicology laboratories, to detect and report events involving 4F-MDMB-BICA.

Chemical and physical properties and the methods and precursors used for manufacture

Chemical and physical properties

Methyl 2-[[1-(4-fluorobutyl)-1*H*-indole-3-carbonyl]amino]-3,3-dimethylbutanoate (4F-MDMB-BICA) is a synthetic cannabinoid receptor agonist (synthetic cannabinoid). The 4F-MDMB-BICA code name used for the substance is derived from its structural features ⁽⁶⁾: a methyl 3,3-dimethylbutanoate linked group (MDMB), a 4-fluorobutyl tail (4F and B) attached to the indole nitrogen atom of an indole core (I), and a carboxamide linker (CA).

⁽²⁾ Including some of its named isomers and their stereochemical variants.

⁽³⁾ And its stereochemical variants.

⁽⁴⁾ 4F-MDMB-BINACA: methyl 2-[[1-(4-fluorobutyl)-1*H*-indazole-3-carbonyl]amino]-3,3-dimethylbutanoate.

⁽⁵⁾ 5F-MDMB-PICA (5F-MDMB-2201): methyl 2-[[1-(5-fluoropentyl)-1*H*-indole-3-carbonyl]amino]-3,3-dimethylbutanoate.

⁽⁶⁾ Different naming systems exist and are used for applying short/code names to synthetic cannabinoids.




<http://www.emcdda.europa.eu/topics/pods/synthetic-cannabinoids>.

4F-MDMB-BICA is structurally related to 4F-MDMB-BINACA (⁴), 5F-MDMB-PICA (5F-MDMB-2201) (⁵), and 5F-MDMB-PINACA (⁷), all of which are under international control (Schedule II of the 1971 United Nations Single Convention on Psychotropic Substances).

The chemical structures, molecular formulae and molecular weights of these compounds are provided in Figure 1.

FIGURE 1

Chemical structures and molecular information of 4F-MDMB-BICA, 4F-MDMB-BINACA, and 5F-MDMB-PICA

4F-MDMB-BICA	4F-MDMB-BINACA	5F-MDMB-PICA
		
Molecular formula: C ₂₀ H ₂₇ FN ₂ O ₃	Molecular formula: C ₁₉ H ₂₆ FN ₃ O ₃	Molecular formula: C ₂₁ H ₂₉ FN ₂ O ₃
Molecular weight: 362.44	Molecular weight: 363.43	Molecular weight: 376.47
Monoisotopic mass: 362.2006	Monoisotopic mass: 363.1958	Monoisotopic mass: 376.2162

In its pure form 4F-MDMB-BICA has been described as a white solid. It is soluble in organic solvents such as chloroform and expected to be only partially soluble in water.

4F-MDMB-BICA contains a stereogenic centre and therefore two possible enantiomers may exist, (*S*)-4F-MDMB-BICA and (*R*)-4F-MDMB-BICA. No information is available on whether the 4F-MDMB-BICA detected in the European drug market corresponds to the (*R*)- or (*S*)-enantiomer, or a mixture of both, which may in part reflect the fact that stereochemical analysis is not routinely undertaken in forensic laboratories. Based on the literature and the

(⁷) 5F-MDMB-PINACA (5F-ADB): 2-[[1-(5-fluoropentyl)-1*H*-indole-3-carbonyl]amino]-3,3-dimethylbutanoate

precursors that are most likely to be used, an (*S*)-configuration of the stereocentre could be expected.

Information provided from seizures and collected samples reported to the EMCDDA have noted that 4F-MDMB-BICA is typically found in herbal/plant material (including as commercially-branded 'legal high' products) and as a powder. Other forms, such as pieces of paper impregnated with the substance (including blotters), liquids and e-liquids have also been reported.

The analytical identification of 4F-MDMB-BICA in physical and biological samples is possible using standard analytical techniques. These include chromatographic and mass spectrometric methods.

Analytical reference material is important for correct identification and for facilitating the quantification of 4F-MDMB-BICA in physical and biological samples. Such material is commercially available in form of the (*S*)-enantiomer.

Methods and precursors used for manufacture

There is no information on the actual manufacturing methods or chemical precursors used to synthesise the 4F-MDMB-BICA that has been identified on the drug market in Europe. Information from one seizure made by customs suggests that at least some 4F-MDMB-BICA on the market in Europe has been supplied from China. Although the synthetic routes reported in the scientific literature involve several steps, they are straightforward and make use of common manufacturing equipment. The starting materials for either synthetic route are readily available. The multi-step production of 4F-MDMB-BICA requires basic knowledge of and experience in synthetic organic chemistry.

Commercially available domestic or industrial chemicals which could be used for synthesis of 4F-MDMB-BICA may be potentially toxic. Use of such products as reagents or solvents may result in serious toxic effects if the resultant contaminated product is consumed. The herbal plant material which is used as a basis for smoking mixtures may also contain toxicologically relevant substances (such as pesticides that could potentially be present in the plant material).

Pharmaceutical forms

Information on the pharmaceutical forms available for 4F-MDMB-BICA is limited. There are three main types of products containing synthetic cannabinoids that are available on the drug market: smoking mixtures, where the cannabinoid is mixed with herbal plant material or tobacco that is then smoked (similar to herbal cannabis, the mixture is usually prepared for smoking as a hand-rolled cigarette ('joint')) or inhaled using a vapouriser; e-liquids, where a solution of the cannabinoid is prepared by mixing it with a solvent, which is then inhaled ('vaped') using an e-cigarette; in addition, synthetic cannabinoids are also impregnated on to paper which can then be smoked or vaped. The latter is a commonly used approach to

smuggle synthetic cannabinoids into prison in some countries. To a lesser extent, people who are using these substances may also prepare their own products using powdered synthetic cannabinoids purchased from a vendor or dealer. It is expected that similar to related synthetic cannabinoids 4F-MDMB-BICA may also be administered orally and sublingually.

Products containing synthetic cannabinoids such as 4F-MDMB-BICA rarely state the correct ingredients and concentrations. Given the illicit nature of the trade in 4F-MDMB-BICA, the composition of products containing 4F-MDMB-BICA is likely to vary over time and place, as well as based on the specific location in the drug supply chain from which the product was obtained (e.g. from the manufacturer, wholesaler, retailer or at street-level illicit market). In Europe, 4F-MDMB-BICA has been seized by law enforcement in the form of powders, smoking mixtures, pieces of paper impregnated with the substance (including blotters), liquids and e-liquids. Information on the amount of 4F-MDMB-BICA present in seized powders (chemical purity) has not been reported. In at least some of the seizures other synthetic cannabinoids were present. Information on the enantiomeric composition of seized and collected samples has not been reported.

Pharmacological and toxicological properties

Pharmacological properties

There is limited information on the pharmacological properties of 4F-MDMB-BICA. Currently available information from *in vitro* studies suggests that 4F-MDMB-BICA activates the cannabinoids type 1 (CB₁) receptor as a full agonist at reasonably high potency. These data show that 4F-MDMB-BICA has comparable potency to JWH-018 that is under international control, but is less potent than 4F-MDMB-BINACA and 5F-MDMB-PICA, which are potent full agonists that are also under international control. This suggests that 4F-MDMB-BICA may produce effects in humans similar to other cannabinoid receptor agonists, such as THC and other synthetic cannabinoids. No information is available on binding and activation of the CB₂ receptor nor the effects induced *in vivo* by 4F-MDMB-BICA.

No studies are available on the pharmacodynamics of 4F-MDMB-BICA on other pharmacological targets.

Data on the pharmacokinetics of 4F-MDMB-BICA, including information on metabolites and their effects, are unavailable.

Toxicological properties

No information is available on the toxicological properties (including pre-clinical safety data) of 4F-MDMB-BICA. Ingestion of highly potent full CB₁ receptor agonists have been associated with acute toxicity in humans; this suggests that the acute toxicity of 4F-MDMB-BICA may be much greater than THC and similar to that observed for related synthetic cannabinoids under international control. The involvement of other, non-cannabinoid

toxicological targets or unexpected drug-drug interactions in the overall pharmacotoxicological effects of 4F-MDMB-BICA cannot be excluded.

There is no known antidote to poisoning caused by synthetic cannabinoids. Treatment in poisoning cases should be symptomatic.

Health risks

No studies are available on the acute and chronic health effects of 4F-MDMB-BICA. The clinical features of poisonings caused by 4F-MDMB-BICA are expected to be similar to those reported from related synthetic cannabinoids resulting in gastrointestinal, neurological, cardiovascular, renal clinical features. These dose-dependent effects appear to be much more pronounced and severe when compared to cannabis.

Acute toxicity

There is limited information on the acute toxicity of 4F-MDMB-BICA. Based on the available information, the health risks are likely to be similar to those observed with other synthetic cannabinoids. Adverse effects from overdosing 4F-MDMB-BICA might include gastrointestinal (e.g. nausea and vomiting (including hyperemesis)), neurological (e.g. hallucination, seizures, convulsions, agitation, anxiety, paranoia, confusion, delusions, catatonia, lethargy, psychosis (including susceptible individuals) and severe central nervous system depression (such as rapid loss of consciousness/coma), cardiovascular (e.g. tachycardia, hypertension, acute myocardial infarction and sudden cardiac death) and renal (e.g. acute kidney failure) clinical features, and respiratory depression.

In addition, some of the features of poisoning—particularly loss of consciousness, respiratory depression, and behavioural effects—may place users at additional risks, such as choking on/aspirating vomit, drowning, falling, hypothermia as a result of falling unconscious outside in cold weather, and self-inflicted violence/injury. The aggressive and violent behaviours reported with synthetic cannabinoids may also place others at risk of injury.

The reasons for these more pronounced and severe effects, as well as severe and fatal poisoning, are poorly understood, but at least two factors are likely to be important: the high potency of the substances and the unintentionally high doses that users are exposed to.

Firstly, studies have found that many of the synthetic cannabinoids, including 4F-MDMB-BICA, which are sold on the drug market, are typically potent, full agonists compared to THC. This means that even at very small doses they can activate the CB₁ receptor much more potently than THC, which may be responsible for the more pronounced and unexpected pharmacotoxicological effects in humans.

Secondly, in respect to smoking mixtures, the process for mixing the synthetic cannabinoids with the plant material to make the smoking mixture can lead to dangerous amounts of the

substances in the products. This is because producers have to guess the amount of substances to be added, while the mixing process makes it difficult to dilute them sufficiently and distribute them consistently throughout the plant material. This can result both in products that contain toxic amounts of the substances in general, as well as in products where solid particles of synthetic cannabinoids are clumped together, forming highly concentrated pockets within the plant material. In fact, in the latter case, simply tapping a packet containing a smoking mixture can dislodge the substances from the plant material. In addition, paper (such as blotters and cards) impregnated with synthetic cannabinoids can pose a similar high risk of poisoning because the amount of synthetic cannabinoid can be unevenly distributed in different parts of the paper, sometimes forming highly concentrated sections on the paper. These issues are exacerbated as the products are typically smoked or vaped, allowing the substances to be rapidly absorbed into the bloodstream and to reach the central nervous system and other parts of the body to cause their effects.

Together, these factors, coupled to the typically high potency of synthetic cannabinoids, makes it difficult for users to control the dose that they are exposed to. This can lead them to rapidly administer a toxic dose unintentionally. Accounts from patients and people who witness poisonings suggest that in some cases a small number of puffs from a cigarette (“joint”) have been sufficient to cause severe and fatal poisoning.

Similarly to other synthetic cannabinoids, the use of 4F-MDMB-BICA together with other drugs, especially central nervous system depressants (such as alcohol, opiates/opioids, and sedative-hypnotics) is likely to increase the risk of life-threatening poisoning.

Acute poisonings

A total of five acute intoxications with confirmed exposure to 4F-MDMB-BICA have been reported to the EMCDDA by the United Kingdom. The cases occurred between June and July 2020. All cases included clinical features of poisoning similar to those reported for other synthetic cannabinoids, such as confusion, tachycardia, respiratory insufficiency, reduced conscious level, abnormal sweating, and agitation. In all cases other substances were identified including other synthetic cannabinoids, benzodiazepines, opioids, and other substances such as pregabalin, cocaine, THC, and ketamine. In all cases the poisoning was considered life threatening and required hospitalisation of the patient.

Deaths

A total of 21 deaths with confirmed exposure to 4F-MDMB-BICA have been reported by Hungary. The deaths occurred between May and August 2020. In the vast majority of cases other substances were identified including other synthetic cannabinoids, benzodiazepines, stimulants, and other substances such as THC, alcohol, and ketamine. Reported ante-mortem symptoms and clinical features included loss of consciousness, chest pain, respiratory problems, tremor, seizures, somnolence, aggressive behaviour, and foaming at the mouth. Three of the cases were found dead. One of the cases involved a prisoner and another involved a homeless person. At least some of the individuals were people known to

use drugs. The reported causes of death were: cardiac arrest due to substance overdose (7 cases), acute heart failure (7 cases), traumatic shock (2 cases), strangulation (1 case), brain oedema (1 case), and asphyxiation following aspirating vomit (1 case).

Physical, mental and behavioural effects

The physical effects of 4F-MDMB-BICA have not been studied. Based on the pharmacological properties of the substance, as well as information from observations from closely related substances, it is likely that the dose-dependent effects of 4F-MDMB-BICA are similar to those commonly reported for other synthetic cannabinoids, including tachycardia, dry mouth, nausea, vomiting, balance deficiencies, and ocular effects such as reddened conjunctivae, glassy eyes and delayed or unresponsive pupil light reactions, and impaired motor performance.

The mental and behavioural effects of 4F-MDMB-BICA have not been studied. Based on the pharmacological properties of the substance, the effects of 4F-MDMB-BICA appear to share some similarities with cannabis, THC, and other synthetic cannabinoids. This may include: relaxation, euphoria, lethargy, confusion, anxiety, fear, distorted perception of time, depersonalisation, hallucinations, and paranoia.

Overall, these effects may be much more pronounced and severe when compared to cannabis. In addition, psychotic episodes, as well as aggressive and violent behaviour, have also been reported.

There are no studies on the effects of 4F-MDMB-BICA on the ability to drive and operate machines. However, synthetic cannabinoids impair the mental and physical ability required to drive and operate machines. This effect is likely to extend to 4F-MDMB-BICA.

Chronic toxicity

There is no information on the chronic toxicity of 4F-MDMB-BICA. Similar to other synthetic cannabinoids, chronic use has been associated with greater risks for developing mental health disorder than cannabis, which may include dependence. Acute and chronic use of synthetic cannabinoids has also been associated with cases displaying detrimental cardiovascular health.

Abuse liability and dependence-producing potential

No information is available on the abuse liability and dependence producing potential of 4F-MDMB-BICA. Given what is currently known about the properties of synthetic cannabinoids in general (and some similarities to THC), it is expected that 4F-MDMB-BICA may have a potential for abuse and dependence. It has been suggested that consumption of synthetic cannabinoids can produce tolerance and withdrawal-like symptoms when use is discontinued following a regular use. Withdrawal-like symptoms following cessation of synthetic cannabinoids have been described in the literature. These include: anxiety,

unstable mood, crying fits, feeling of inner emptiness, spatial disorientation, hyperacusis (increased sensitivity to ordinary environmental sounds), somatic pain, shortness of breath, hyperventilation, intense sweating and sensations of motor and inner restlessness.

Social risks

There is no specific information on the social risks posed by 4F-MDMB-BICA. There is no information on whether or not criminal groups are involved in the manufacture, trafficking and distribution of 4F-MDMB-BICA within Europe.

It is possible that any such social risks may have some similarities with those associated with the use of cannabis and other synthetic cannabinoids. Such risks include negative impacts on social functioning and criminal activities, such as the involvement of organised crime in the manufacture, trafficking and distribution of the substance.

It is noteworthy that in some settings, synthetic cannabinoids are increasingly used by high-risk drug users and other vulnerable groups, such as the homeless and prisoners. In at least some cases, these people are specifically seeking out synthetic cannabinoids because the substances have developed a reputation for causing profound intoxication. They are also considered cheap, and easy to smuggle. Reports suggest that this has exacerbated existing health and social problems for these vulnerable groups, as well as creating new ones.

In prisons, alongside the adverse health effects, the market in and use of synthetic cannabinoids has been linked to an increase in aggression, violence, bullying, and debt. In some cases, this has caused a serious threat to the overall safety and security of the prison environment.

Extent and patterns of use, availability and potential for diffusion

There is limited information on the extent and patterns of use, availability and potential for diffusion of 4F-MDMB-BICA in Europe. As 4F-MDMB-BICA has been on the drug market for only a short period of time, no formal epidemiological studies have been conducted, which limits the understanding of the extent and patterns of use, as well as the potential for diffusion. In relation to this, the presence of 4F-MDMB-BICA on the drug market and its involvement in serious adverse events may be undetected in some areas because the substance is not routinely screened for in some forensic and toxicology laboratories.

4F-MDMB-BICA has been available on the drug market in Europe since at least March 2020, when it was seized for the first time by customs in Belgium. As of November 2020, 4F-MDMB-BICA has been identified in twelve Member States: Belgium, Croatia, Cyprus, Finland, Germany, Hungary, Italy, Lithuania, Poland, Slovenia, Sweden, and the United Kingdom. A total of 111 seizures have been reported, which include 5.6 kg of powder and 0.6 kg of smoking mixtures. Of particular note are four large scale seizures of 4F-MDMB-BICA powder reported by Belgian customs (totalling approximately 5.5 kg) and eleven

seizures that occurred in prisons in five Member States. The most recent identifications of 4F-MDMB-BICA reported to the EMCDDA are from seizures made by police in Cyprus and customs in Finland in September 2020. Of note is that 4F-MDMB-BICA has been increasingly identified in biological samples in parts of Germany during the last few months of 2020.

Based on the available information, it appears that at least some of the 4F-MDMB-BICA on the market in Europe has been supplied from China. It is imported into Europe as bulk powders and then sold and distributed in wholesale and retail amounts within Europe either as a powder for processing into products or finished consumer products. There are three main types of products containing 4F-MDMB-BICA that are available on the drug market: smoking mixtures, where 4F-MDMB-BICA is mixed with herbal plant material or tobacco that is then smoked (similar to herbal cannabis, the mixture is usually prepared for smoking as a hand-rolled cigarette ('joint')) or inhaled, for example using a vaporiser; e-liquids, where a solution of 4F-MDMB-BICA is prepared by mixing it with a solvent, which is then inhaled using an e-cigarette; in addition, 4F-MDMB-BICA is also impregnated on to paper which can then be smoked or vaped. In some countries, the latter is a commonly used approach to smuggle synthetic cannabinoids into prisons. To a lesser extent, people who are using these substances may prepare their own similar products using 4F-MDMB-BICA purchased from a vendor or dealer.

4F-MDMB-BICA may be sought by those looking for 'legal' substitutes for cannabis. This includes individuals subject to drug testing (such as drivers, prisoners, those in drug treatment, and those subject to workplace drug testing), as commonly used drug tests may be unable to detect the compounds. In addition, reports suggest that in some areas, high risk drug users and other vulnerable groups, such as homeless people and prisoners, may specifically seek out synthetic cannabinoids because they have a reputation for causing profound intoxication. They are considered to be cheap and easy to smuggle. Similar to other new psychoactive substances, it also appears that there is interest in 4F-MDMB-BICA by people who self-experiment with a range of substances (so-called psychonauts). Overall, the available information does not suggest widespread use of the substance.

Limited information is available regarding the dose and the dose regimens of 4F-MDMB-BICA. User reports specifically about 4F-MDMB-BICA were not particularly revealing. It is not possible to discern the 'typical' dosages administered as most individuals use pre-made smoking mixtures. Synthetic cannabinoids such as 4F-MDMB-BICA may be active at less than 1 mg. Products containing synthetic cannabinoids such as 4F-MDMB-BICA rarely state the correct ingredients and concentrations. As such, people who use such products will be unaware that they are using 4F-MDMB-BICA nor will they be able to obtain accurate dosage information. 4F-MDMB-BICA can be inhaled by smoking and by vaporising e-liquid solutions ('vaping'), for example by using electronic cigarettes. To a lesser extent, other routes of administration for synthetic cannabinoids have been reported; these include oral, sub-lingual, and rectal.

The high potency of the synthetic cannabinoids, coupled to the unintentionally high doses that users are potentially exposed to, is responsible for outbreaks of mass poisonings involving smoking mixtures. Such outbreaks have ranged in size from four or five to over 800 victims, including deaths. While many of the outbreaks that have been reported so far are from the United States, they have also occurred in Russia and Europe. Mass poisonings can rapidly overwhelm emergency responders and other local healthcare systems.

Unknown to users, synthetic cannabinoids have also been sold as cannabis, ecstasy (MDMA) and other illicit drugs. In some cases, this has led to severe poisoning. Opioids have also been identified in smoking mixtures; while the overall number of detections appears to be relatively small, they could pose a risk of severe opioid poisoning, including life-threatening respiratory depression, especially in individuals with no tolerance to opioids. Users of smoking mixtures will be unaware of this risk.

Commercial and industrial uses, the extent of such use and its use for scientific research and developmental purposes

Based on the available information reported to the EMCDDA from the EMA, it appears that 4F-MDMB-BICA is not an active substance in any medicinal product for human use or in any veterinary medicinal product in Europe. However, although unlikely, the use of 4F-MDMB-BICA as an active substance in medicinal products prepared extemporaneously or in investigational medicinal products cannot be excluded in some Member States.

There is currently no information suggesting that 4F-MDMB-BICA is used for legitimate purposes, including commercial and industrial uses, other than a scientific research or forensic application.

Other relevant information

Restrictive measures

International restrictive measures

At international level, 4F-MDMB-BICA is not controlled under the United Nations Single Convention on Narcotic Drugs, 1961, nor under the Convention on Psychotropic Substances of 1971. 4F-MDMB-BICA has not been subject to assessment nor is it currently under assessment by the United Nations system.

National restrictive measures

Fifteen Member States (Bulgaria, Czechia, Denmark, Estonia, Finland, Greece, Ireland, Malta, the Netherlands, Portugal, Romania, Slovakia, Slovenia, Spain, and Sweden) reported that 4F-MDMB-BICA is not subject to restrictive measures at national level.

4F-MDMB-BICA is subject to restrictive measures in thirteen Member States. Eight Member States (Croatia, Cyprus, France, Italy, Latvia, Luxembourg, Poland, and the United Kingdom) control 4F-MDMB-BICA under drug control legislation. One Member State (Lithuania) controls 4F-MDMB-BICA under medicines legislation. Four Member States (Austria, Belgium, Germany, and Hungary) control 4F-MDMB-BICA under new psychoactive substance legislation. In addition, 4F-MDMB-BICA is controlled under medicines legislation in Norway and under drug control legislation in Turkey.

It is unknown if 4F-MDMB-BICA is controlled in China, where at least some of the substance on the European market has been sourced from.

COVID-19 pandemic

In some settings, the on-going COVID-19 pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may have reduced the capacity of early warning systems, including forensic science and toxicology laboratories, to detect and report events involving 4F-MDMB-BICA.

Conclusion

4F-MDMB-BICA (methyl 2-[[1-(4-fluorobutyl)-1*H*-indole-3-carbonyl]amino]-3,3-dimethylbutanoate) is an indole-based synthetic cannabinoid receptor agonist (synthetic cannabinoid). The (*S*)-4F-MDMB-BICA stereoisomer has been shown to act as a potent, full agonist at the cannabinoid type 1 (CB₁) receptor when investigated under *in vitro* conditions. This suggests that in humans, 4F-MDMB-BICA may produce similar effects both to THC, which is responsible for the major psychoactive effects of cannabis, and, in particular, closely related synthetic cannabinoids that are under international control, such as 4F-MDMB-BINACA and 5F-MDMB-PICA.

4F-MDMB-BICA is often sold as a 'legal' replacement for cannabis and other synthetic cannabinoids. It is typically administered by smoking a mixture of the substance with herbal plant material or tobacco. These are either from a ready-to-use products sold as commercial 'legal high' products or made by drug dealers; less commonly they are self-prepared. Similar to herbal cannabis, the mixture is usually prepared for smoking as a hand-rolled cigarette ('joint') but it may also be smoked in a pipe or 'bong'. 4F-MDMB-BICA can also be inhaled using an e-cigarette or other vaporisation devices. In the case of impregnated papers, typically these are either smoked with tobacco or vaped using an e-cigarette.

The high potency of synthetic cannabinoids and the variable content of the substance in products such as smoking mixtures and impregnated papers constitute a high risk of poisoning, which can be life-threatening or even fatal. These factors are responsible for the outbreaks of mass poisonings seen with synthetic cannabinoids. Although no mass poisonings have been reported for 4F-MDMB-BICA, it is used in a context making it liable to the occurrence of mass poisonings. Such outbreaks have the potential to overwhelm local healthcare systems, which is of particular concern given the on-going COVID-19 pandemic and the additional burden already on healthcare systems. There is no antidote to poisoning caused by synthetic cannabinoids.

4F-MDMB-BICA has been available in Europe since at least March 2020 and has been identified in 12 Member States (Belgium, Croatia, Cyprus, Finland, Germany, Hungary, Italy, Lithuania, Poland, Slovenia, Sweden, and the United Kingdom). 4F-MDMB-BICA has been identified in smoking mixtures, powders, paper impregnated with the substance (including blotters), and liquids (including e-liquids). Of note is that the appearance of 4F-MDMB-BICA on the market appears to coincide with the recent decision to internationally control two closely related synthetic cannabinoids commonly found on the drug market in Europe, 4F-MDMB-BINACA and 5F-MDMB-PICA. As such, it is conceivable that 4F-MDMB-BICA will be a replacement for these substances. Of note is that 4F-MDMB-BICA has been increasingly identified in biological samples in parts of Germany during the last few months of 2020.

As with other synthetic cannabinoids, the available data suggests that 4F-MDMB-BICA is used by people who use cannabis, by those who are regularly subjected to drug testing procedures, and by 'psychonauts'. It may also be used by high-risk drug users and other vulnerable groups (such as prisoners and people experiencing homelessness) as synthetic

cannabinoids have gained a reputation for causing profound intoxication, they are cheaper than other drugs, and easy to smuggle. No information is available on the size and demand and the characteristics of these groups of people.

Five acute intoxications with confirmed exposure to 4F-MDMB-BICA have been reported to the EMCDDA by the United Kingdom. The cases occurred between June and July 2020. While exposure to other substances was reported in most cases, including other synthetic cannabinoids, at least some of the clinical features of the poisonings were consistent with exposure to synthetic cannabinoids. In all cases the poisoning was considered life threatening and required hospitalisation of the patients.

Twenty-one deaths with confirmed exposure to 4F-MDMB-BICA have been reported by Hungary. The deaths occurred over relatively short period of time, between May and August 2020. In the vast majority of cases other substances, including other synthetic cannabinoids, were identified. In at least some of these cases, 4F-MDMB-BICA may have contributed to the death.

As 4F-MDMB-BICA has emerged on the drug market in Europe only recently, it is important to note that its presence on the drug market and as the cause of serious adverse events may be undetected because the substance is not routinely screened for in some laboratories. In addition, the on-going COVID-19 pandemic may have reduced the capacity of early warning systems to detect and report events involving 4F-MDMB-BICA.

There is no information available on the chronic health effects of 4F-MDMB-BICA, including abuse liability and dependence producing potential. The chronic health risks might share some similarities to those seen with other synthetic cannabinoids. This may include dependence.

There is no information on whether or not criminal groups are involved in the manufacture, trafficking and distribution of 4F-MDMB-BICA within the European Union. The available information suggests that at least some of the 4F-MDMB-BICA seized in Europe is manufactured by chemical companies based in China. The impact of the on-going COVID-19 pandemic on the manufacture, trafficking, distribution and use of 4F-MDMB-BICA is also currently unknown. However, seizures of bulk powders by European national customs agencies during the first wave of the epidemic highlight that it has been imported into and distributed within Europe during 2020. It is conceivable that should there be a reduced availability of cannabis and other synthetic cannabinoids in Europe, criminal groups as well as people who use drugs, may use a range of replacement substances, including 4F-MDMB-BICA.

There is no information on the actual chemical precursors or manufacturing methods used to synthesise the 4F-MDMB-BICA that has been identified on the drug market in Europe. Although the synthetic routes reported in the scientific literature involve several steps, depending on precursor availability, they are straightforward and make use of common manufacturing equipment. The starting materials for either synthetic route are readily

available. The multi-step production of 4F-MDMB-BICA requires a basic knowledge of and experience in synthetic organic chemistry.

There is no specific information available on the potential social risks posed by 4F-MDMB-BICA. The social risks might share some similarities with those posed cannabis and other synthetic cannabinoids. As highlighted, synthetic cannabinoids are increasingly used by high-risk drug users and vulnerable groups, such as prisoners and people experiencing homelessness, which has exacerbated existing health and social problems as well as creating new issues. For example, in prisons, alongside the adverse health effects, the market in and use of synthetic cannabinoids has been linked to an increase in aggression, violence, bullying, and debt. In some cases, this has caused a serious threat to the overall safety and security of the prison environment. As such, it is a concern given the reports of seizures of 4F-MDMB-BICA in prisons and other custodial settings in at least five Member States.

There is currently limited information on the extent or patterns of use of 4F-MDMB-BICA in Europe, nevertheless, information from law enforcement seizures that occurred in 2020 suggest that its availability and potential for diffusion within the Union may be significant. Based on the available information, the consumption of 4F-MDMB-BICA appears to have the potential to cause harms to health associated with its acute toxicity and abuse liability or dependence-producing potential. This harm to health is considered life-threatening because it may cause death. There is also a potential for severe physical and mental impairment. In addition, although limited, information suggests potential social harms related to consumption of 4F-MDMB-BICA including from use in prisons. Overall, these effects appear to be comparable to those of other closely related synthetic cannabinoids that are under international control, such as 4F-MDMB-BINACA and 5F-MDMB-PICA.

It appears that 4F-MDMB-BICA is not an active substance in any medicinal product for human use or in any veterinary medicinal product in Europe. However, although unlikely, the use of 4F-MDMB-BICA as an active substance in medicinal products prepared extemporaneously or in investigational medicinal products cannot be excluded in some Member States. There is currently no information suggesting that 4F-MDMB-BICA is used for legitimate purposes other than research or forensic applications in Europe.

4F-MDMB-BICA is not listed for control in the Single Convention on Narcotic Drugs, 1961, nor in the Convention on Psychotropic Substances, 1971. 4F-MDMB-BICA is not currently under assessment by the United Nations system.

Eight Member States (Croatia, Cyprus, France, Italy, Latvia, Luxembourg, Poland, and the United Kingdom) and Turkey control 4F-MDMB-BICA under drug control legislation. Five Member States (Austria, Belgium, Germany, Hungary, and Lithuania) and Norway control 4F-MDMB-BICA under other legislation. It is unknown if 4F-MDMB-BICA is controlled in China, where at least some of the substance on the European market has been sourced from.

The Committee notes that while the available information on 4F-MDMB-BICA indicates that it is a potent synthetic cannabinoid *in vitro*, overall there is limited information available on its pharmacology, toxicology, abuse liability and dependence-producing potential. Additional information may emerge with later studies but ideally would have been available in this assessment. The Committee notes that, to strengthen early warning, preparedness and response activities within the EU, such studies should be undertaken systematically prior to risk assessment.

As for any NPS, many of the questions related to 4F-MDMB-BICA that are posed by the lack of data on the risks to individual health, risks to public health and social risks could be answered through further research. Areas where additional information would be important include studies on epidemiology (frequency and patterns of use, including studies that examine the groups of people who use 4F-MDMB-BICA and risk behaviours); the market; chemical profiling; extended pharmacological profiling; metabolic pathways; behavioural effects; acute and chronic toxicity; the potential interaction between 4F-MDMB-BICA and other substances; the abuse liability and dependence-producing potential; and the public health and potential social risks associated with its use.

The Committee notes that a decision to control 4F-MDMB-BICA has the potential to bring with it both intended and unintended consequences. Potential intended consequences include reduced levels of availability and ultimately use. This may reduce the health and social risks arising from the use of 4F-MDMB-BICA. It is important to recognise that a potential unintended consequence of control may be the manufacture and availability of other substances. Indeed, pharmacologically analogous substances that may replace 4F-MDMB-BICA are already being sold on the drug market. The implementation of control measures may also lead to the criminalisation of those who continue to use this substance with the possible attendant risks of socio-economic stigmatisation and marginalisation.

Finally, the Committee notes that it is important to continue to collect accurate information on 4F-MDMB-BICA and to disseminate it to people who use the substance, as well as to practitioners, policymakers and decision-makers.

ANNEX 1

Technical report on the new psychoactive substance methyl 2-[[1-(4-fluorobutyl)-1*H*-indole-3-carbonyl]amino]-3,3-dimethylbutanoate (4F-MDMB-BICA)

Purpose

The purpose of this technical report is to provide an analysis of the available information on methyl 2-[[1-(4-fluorobutyl)-1*H*-indole-3-carbonyl]amino]-3,3-dimethylbutanoate (4F-MDMB-BICA), a synthetic receptor cannabinoid agonist that has recently emerged on the drug market in Europe, in order to support the risk assessment of the substance which has been requested by the European Commission in accordance with Article 5c of Regulation (EC) No 1920/2006 (as amended).

Parts of this report were prepared under an EMCDDA contract (ref. CT.20.SAS.0108.1.0).

Statement regarding the United Kingdom

The reference period for this technical report includes 2020 (up to 24 November 2020). The United Kingdom left the European Union as of 1 February 2020. However, during the transitional period, the United Kingdom continues to participate in the European Union Early Warning System on new psychoactive substances. Unless stated otherwise, for the purpose of this report, the term 'Member States' shall include the United Kingdom.

Information sources

The information in this technical report is derived from:

- Information reported by the Member States, Turkey, and Norway to the EMCDDA and Europol in accordance with the requirements of Article 5a and Article 5b of Regulation (EC) No 1920/2006 (as amended)
- Information reported by the European Medicines Agency (EMA), the European Chemicals Agency (ECHA), the European Centre for Disease Prevention and Control (ECDC), and the European Food Safety Authority (EFSA) to the EMCDDA in accordance with the requirements of Article 5b of Regulation (EC) No 1920/2006 (as amended)
- Information collected by the EMCDDA through searches of open source information, including the scientific and medical literature, patents, official reports, grey literature, online drug discussion forums and related websites, and online vendors selling 4F-MDMB-BICA.

Search strategy

Literature searches used both chemical structure and textual queries in online databases; searches were conducted in October 2020. The retrieved publications were then scanned for additional relevant references (snowballing technique).

SciFinder® and Reaxys were searched by exact structure-based search. PubMed, Web of Science and Google Scholar were searched for '4F-MDMB-BICA', IUPAC names, and the various other code names stated in this document. The references were screened for relevance and included in the review where appropriate.

Additionally, the scientific networks of the authors were contacted to obtain information.

Terminology and definitions

The terminology and definitions used in this technical report are based on those used for the operation of the EU Early Warning System on new psychoactive substances, including those related to relevant internal EMCDDA processes. They can be accessed at: <http://www.emcdda.europa.eu/system/files/publications/12213/downloads/Guidance%20Note%201-%20Terminology%20and%20definitions.pdf> (EMCDDA, 2019).

Unless otherwise indicated, the terms and definitions are for operational use only and do not have legal meaning. They may differ from those used in other settings and by other organisations (EMCDDA, 2019).

Technical report prepared by

Joanna De Morais (EMCDDA), Simon Brandt (Liverpool John Moores University), Rita Jorge (EMCDDA), Rachel Christie (EMCDDA), Ana Gallegos (EMCDDA), Roumen Sedefov (EMCDDA), Michael Evans-Brown (EMCDDA)

Acknowledgements

The EMCDDA would like to thank the following for their contribution in producing this technical report:

- the Early Warning System (EWS) correspondents of the Reitox national focal points (NFPs) and experts from their national EWS networks;
- the Europol national units (ENUs) and Europol Project Synergy;
- the national competent authorities responsible for human and veterinary medicinal products in the Member States, Norway, Iceland and Liechtenstein;
- the European Medicines Agency (EMA), the European Chemicals Agency (ECHA), the European Centre for Disease Prevention and Control (ECDC), the European Food Safety Authority (EFSA), and the European Commission;
- Public Health Agency of Sweden (PHA) and National Board of Forensic Medicine (NBFM), Sweden;

- Prof. Christophe P Stove, Ghent University, Belgium, and Dr Samuel D Banister, University of Sydney, Australia;
- Dr Craig McKenzie, Leverhulme Research Centre for Forensic Science (LRCFS), University of Dundee;
- Prof. Volker Auwärter, University of Freiburg, Germany;
- Dr István Ujváry, iKem BT, Budapest, Hungary.

1. Summary

Synthetic cannabinoid receptor agonists (synthetic cannabinoids), such as 4F-MDMB-BICA, are a group of substances that mimic the effects of tetrahydrocannabinol (THC), which is a substance found in cannabis (1). THC is responsible for many of the psychoactive effects of cannabis which are dose-dependent and include relaxation, euphoria, distorted perception of time, and impaired motor performance (the feeling of being 'stoned' or 'high'), as well as confusion, anxiety, occasional hallucinations and paranoia, dry mouth, bloodshot eyes, and cardiovascular effects (Gaoni and Mechoulam, 1964; Huestis et al., 2001; Pertwee, 2014). THC causes these effects by activating a receptor in the brain called the cannabinoid receptor type 1 (CB₁ receptor) (Huestis et al., 2001; Pertwee, 2005a). This receptor is part of a signalling system in the body called the endocannabinoid system, which helps regulate, among other things, behaviour, mood, pain, appetite, sleep, and the immune system (Pertwee, 2015) (2). Because synthetic cannabinoids activate the CB₁ receptor, some of their effects appear to be similar to cannabis. Most prominently, they are able to create a feeling of being 'stoned'.

Synthetic cannabinoids were originally developed to study the endocannabinoid system, as well as provide insights into disease states, and to help develop new medicines (Pertwee, 2005a; Pertwee, 2005b; Pertwee, 2015; Reggio, 2009). In around 2006, some of these substances began to appear in Europe in products called 'Spice' that were sold as 'legal' replacements to cannabis (Auwärter et al., 2009; EMCDDA, 2009; Jack, 2009). In these products, synthetic cannabinoids were found to be mixed with plant (herbal) material which could then be smoked as cigarettes ('joints') (Auwärter et al., 2009; EMCDDA, 2009; EMCDDA, 2017; Jack, 2009). Such products have been referred to by a variety of names that depend on the country, region, product type, brand names, and user groups. Names include: 'smoking mixtures', 'herbal smoking mixtures', 'herbal incense', 'synthetic cannabis', 'legal weed', and 'K2'. A common name used in Hungary is 'magic tobacco'; in France 'chimique'; in Turkey, 'Bonsai'; whereas in Birmingham, United Kingdom, the name 'Black Mamba' or simply 'Mamba' is used. Since 2008, more than 200 synthetic cannabinoids have been identified on the drug market in hundreds of different products. They are the largest group of substances that are monitored by the EMCDDA through the European Union Early Warning System on New Psychoactive Substances (EU Early Warning System). In recent years, alongside smoking mixtures, new dosage forms,

(1) (-)-*trans*- Δ^9 -tetrahydrocannabinol.

(2) The endocannabinoid system helps regulate a large number of functions in the body. It consists of the cannabinoid CB₁ and CB₂ receptors, the endocannabinoids (such as anandamide) which act as endogenous agonists for these receptors, and the processes responsible for endocannabinoid biosynthesis, cellular uptake, and metabolism. Important exogenous agonists for the cannabinoid receptors are (-)-*trans*- Δ^9 -tetrahydrocannabinol (THC) which is the major active substance in cannabis, and the synthetic cannabinoids found in herbal mixtures smoked like cannabis. Data from laboratory studies suggests that the endocannabinoid system is involved in important biological processes many of which await exploration. For example, in response to some diseases, the body increases the amount of endocannabinoids it produces which can reduce unwanted symptoms or slow disease progression (Pertwee, 2005a; Pertwee, 2005b; Pertwee, 2015). It has also been recognized that endocannabinoids, as well as the structurally distinct phytocannabinoids and synthetic cannabinoids, which show an astonishing structural diversity, affect other neurotransmitter systems, such as the dopaminergic, glutamatergic, and GABAergic systems.

including e-liquids for vaping using electronic cigarettes, as well as paper (including blotters) impregnated with synthetic cannabinoids, have appeared on the drug market.

In Europe, 4F-MDMB-BICA is monitored as a new psychoactive substance by the EMCDDA in accordance with Council Framework Decision 2004/757/JHA (as amended) and Regulation (EC) No 1920/2006 (as amended) (EMCDDA, 2020a). The substance has been available on the drug market in Europe since at least March 2020. As 4F-MDMB-BICA has only recently emerged on the drug market, there is limited information on the substance. Formal epidemiological studies have not been conducted, which limits understanding of the use and patterns of use of 4F-MDMB-BICA. In addition, it is important to note that the presence of 4F-MDMB-BICA on the market and as the cause of serious adverse events (such as from acute poisonings presenting to hospital emergency rooms and medico-legal death investigations) may be undetected since the substance is not routinely screened for in some laboratories. It is also important to note that, in some settings, the on-going COVID-19 pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (ECDC, 2020; EMCDDA, 2020e; WHO, 2020b) may have reduced the capacity of early warning systems, including forensic and toxicology laboratories, to detect and report events involving 4F-MDMB-BICA.

As of November 2020, 4F-MDMB-BICA has been identified in twelve Member States; 111 seizures have been reported, which include 5.6 kg of powder and 0.6 kg of smoking mixtures. Of particular note are four large scale seizures of 4F-MDMB-BICA powder reported by Belgian customs amounting to approximately 5.5 kg and eleven seizures that occurred in prisons in five Member States. The most recent identifications of 4F-MDMB-BICA reported to the EMCDDA are from seizures made by police in Cyprus and customs in Finland in September 2020.

Although 4F-MDMB-BICA has not been formally studied in humans, limited information suggests that 4F-MDMB-BICA is a potent CB₁ receptor agonist and, as such, shares some pharmacological similarities with Δ^9 -tetrahydrocannabinol (THC) and other synthetic cannabinoids. Compared to cannabis, severe and fatal poisoning appears to be more common with synthetic cannabinoids. Poisoning may include rapid loss of consciousness/coma, cardiovascular effects (such as hypertension, tachycardia, bradycardia, chest pain, myocardial infarction, and stroke), seizures and convulsions, vomiting (including hyperemesis), delirium, agitation, psychosis, and aggressive and violent behaviour. Cases of sudden death have also been reported. There is no known antidote to poisoning caused by synthetic cannabinoids and thus the treatment of an overdose is the same as that of cannabis toxicity: supportive treatment and serial reassessment of the airway and neurological signs. Because of their high potency and the unintentionally high doses that users may be exposed to, synthetic cannabinoids can pose a high risk of severe poisoning, which in some cases can be fatal. These factors can also be responsible for the outbreaks of mass poisonings seen with synthetic cannabinoids. Such outbreaks have the potential to overwhelm local healthcare systems, which is of particular concern given the on-going COVID-19 pandemic and the additional burden already on healthcare systems.

There is no information on the chronic health effects of 4F-MDMB-BICA. The chronic health risks might share some similarities to those seen with cannabis and other synthetic cannabinoids; this may include dependence.

A total of five acute non-fatal poisonings with confirmed exposure to 4F-MDMB-BICA were reported to the EMCDDA by one Member State, the United Kingdom. All the cases included clinical features of poisoning similar to those reported for other synthetic cannabinoids. In all cases other substances were identified, including other synthetic cannabinoids. In all of the cases, the poisoning was considered life-threatening and required hospitalisation of the patient.

A total of twenty-one deaths with confirmed exposure to 4F-MDMB-BICA have been reported to the EMCDDA by one Member State, Hungary. The deaths occurred over relatively short period of time, between May and August 2020. In all cases other substances were identified, including other synthetic cannabinoids.

The available information suggests that 4F-MDMB-BICA is manufactured by chemical companies based in China. It is imported into Europe as bulk powders and then sold and distributed in wholesale and retail amounts within Europe either as a powder for processing into products or finished consumer products. There are three main types of products containing 4F-MDMB-BICA that are available on the drug market: smoking mixtures, where 4F-MDMB-BICA is mixed with herbal plant material or tobacco that is then smoked (similar to herbal cannabis, the mixture is usually prepared for smoking as a hand-rolled cigarette ('joint')) or inhaled using a vaporiser; e-liquids, where a solution of 4F-MDMB-BICA is prepared by mixing it with a solvent, which is then inhaled ('vaped') using an e-cigarette; in addition, 4F-MDMB-BICA is also impregnated on to paper which can then be smoked or vaped. The latter is a commonly used approach to smuggle synthetic cannabinoids into prison in some countries. To a lesser extent, people who are using these substances may also prepare their own products using powdered 4F-MDMB-BICA purchased from a vendor or dealer.

The available information suggests that 4F-MDMB-BICA may be used by cannabis users, by those who are regularly subjected to drug testing procedures (including those in prison), and by people who self-experiment with a range of psychoactive substances (so-called 'psychonauts'). The substance may also be used by high-risk drug users and other marginalised groups, such as people experiencing homelessness and prisoners, as synthetic cannabinoids are typically readily available, and have gained a reputation for causing profound intoxication while being comparatively cheaper to other drugs. Although limited, there is some information to suggest a recent increase in vaping of synthetic cannabinoids using electronic cigarettes by young people, including teenagers, in some Member States; in some cases, the users believed that they were using cannabidiol (CBD) or THC.

There is no information whether or not criminal groups are involved in the manufacture, trafficking, and distribution of 4F-MDMB-BICA within Europe (EMCDDA, 2020b). The effect of the on-going COVID-19 pandemic (ECDC, 2020; EMCDDA, 2020e; WHO, 2020b) on the manufacture, trafficking, distribution, and use of 4F-MDMB-BICA is currently unknown. However, seizures of bulk powders by European national customs agencies during the pandemic suggests that it continues to be imported into and distributed within Europe. It is conceivable that should there be a reduced availability of cannabis and other synthetic cannabinoids in Europe, criminal groups as well as people who use drugs, may use a range of replacement substances, including 4F-MDMB-BICA.

There is no information on the social harms that may be caused by 4F-MDMB-BICA. Despite this, it is likely that some of the risks are similar to those associated with the use of cannabis and other synthetic cannabinoids. For example, in prisons, alongside the adverse health effects, such as acute poisonings, the market in synthetic cannabinoids has been linked to an increase in bullying and debt, as well as aggression and violence. In some cases, this has caused a serious threat to the overall safety and security of the prison environment. This is a concern given the reports of seizures of 4F-MDMB-BICA in prisons and other custodial settings in at least five Member States.

Based on the available information, it appears that 4F-MDMB-BICA is not an active substance in a medicinal product for human use or in a veterinary medicinal product in Europe. However, although unlikely, the use of 4F-MDMB-BICA as an active substance in medicinal products prepared extemporaneously or in investigational medicinal products cannot be excluded in some Member States (EMCDDA, 2020b). There is currently no information that suggests 4F-MDMB-BICA is used for legitimate purposes other than research or forensic application (EMCDDA, 2020b).

4F-MDMB-BICA is not controlled under the United Nations Single Convention on Narcotic Drugs, 1961, as amended by the 1972 Protocol, nor the Convention on Psychotropic Substances of 1971 ('United Nations system') (UNODC, 2020a; UNODC, 2020b). 4F-MDMB-BICA has not been subject to assessment nor is it currently under assessment by the United Nations system (EMCDDA, 2020b).

4F-MDMB-BICA is subject to restrictive measures in thirteen Member States: in Croatia, Cyprus, France, Italy, Latvia, Luxembourg, Poland, and the United Kingdom the substance is controlled under drug control legislation; in Lithuania it is controlled under medicines legislation; in Austria, Belgium, Germany, and Hungary it is controlled by new psychoactive substance legislation. In addition, 4F-MDMB-BICA is controlled under medicines legislation in Norway and under drug control legislation in Turkey. It is unknown if 4F-MDMB-BICA is controlled in China, where at least some of the substance on the European market appears to have been sourced from (EMCDDA, 2020b).

2. Chemical and physical properties, methods and the precursors used for manufacture or extraction

2.1 Background

Methyl 2-[[1-(4-fluorobutyl)-1*H*-indole-3-carbonyl]amino]-3,3-dimethylbutanoate (4F-MDMB-BICA) ⁽³⁾ – also known as methyl 2-[[1-(4-fluorobutyl)-1*H*-indol-3-yl]carbonyl]amino)-3,3-dimethylbutanoate – (Figure 1), is a synthetic cannabinoid receptor agonist which does not appear to have a history in the scientific literature. However, it is structurally related to compounds of the indazole-3-carboxamide class that feature pendant amino acid esters (methyl L-tert-leucinate) previously developed by Pfizer Inc. and published in 2009 (e.g. compounds 125-130; Buchler et al., 2009). The switch to an indole core not covered by the Pfizer patent reflects an example of scaffold hopping (Banister and Connor, 2018). The substances described in the patent literature make reference to compounds that only show the (*S*)-configuration (e.g. Buchler et al., 2009). As far as it is known, synthetic cannabinoids available on the drug market have generally been found to retain the (*S*)-configuration although the presence of (*R*)-enantiomers or racemic mixtures cannot be excluded. According to information reported to the EMCDDA, 4F-MDMB-BICA has been available on the European drug market at least since March 2020 (EMCDDA, 2020d).

4F-MDMB-BICA is structurally related to 4F-MDMB-BINACA ⁽⁴⁾ (indazole instead of indole core) and 5F-MDMB-PICA (5F-MDMB-2201) ⁽⁵⁾ (homologue) (Figure 1). In 2020, these two synthetic cannabinoids were placed in Schedule II of the 1971 United Nations Single Convention on Psychotropic Substances (CND, 2020) after undergoing a critical review by the World Health Organization's Expert Committee on Drug Dependence in October 2019 (WHO, 2019a; WHO, 2019b).

4F-MDMB-BICA is also structurally related to 5F-MDMB-PINACA (5F-ADB) ⁽⁶⁾. 5F-MDMB-PINACA was formally notified in January 2015 and underwent EMCDDA risk assessment in November 2017 following reports of increasing availability and serious harms in Europe, including 28 deaths (EMCDDA, 2018). In 2018, 5F-MDMB-PINACA was placed in Schedule II of the 1971 United Nations Single Convention on Psychotropic Substances (INCB, 2019) after undergoing a critical review by the WHO's ECDD in November 2017 (WHO, 2017). In 2020, the EMCDDA also launched an initial report on MDMB-4en-BINACA ⁽⁷⁾ in accordance with Article 5b of Regulation (EC) No 1920/2006 (as amended)

⁽³⁾ 4F-MDMB-BICA and many other synthetic cannabinoids described in this report contain one asymmetric carbon atom which gives rise to (*S*)- and (*R*)-enantiomers. The code names described in this report do not include the designated, absolute configuration since the available data were not consistently available to EMCDDA.

⁽⁴⁾ 4F-MDMB-BINACA IUPAC name: methyl 2-[[1-(4-fluorobutyl)-1*H*-indazole-3-carbonyl]amino]-3,3-dimethylbutanoate

⁽⁵⁾ 5F-MDMB-PICA IUPAC name: methyl 2-[[1-(5-fluoropentyl)-1*H*-indole-3-carbonyl]amino]-3,3-dimethylbutanoate

⁽⁶⁾ 5F-MDMB-PINACA IUPAC name: methyl 2-[[1-(5-fluoropentyl)-1*H*-indazole-3-carbonyl]amino]-3,3-dimethylbutanoate

⁽⁷⁾ MDMB-4en-PINACA IUPAC name: methyl 3,3-dimethyl-2-[[1-(pent-4-en-1-yl)-1*H*-indazole-3-carbonyl]amino]butanoate




(EMCDDA, 2020c). MDMB-4en-BINACA was also critically reviewed by the WHO's ECDD in October 2020 (WHO, 2020a).

2.2 Names and chemical structure

4F-MDMB-BICA is a synthetic cannabinoid receptor agonist (synthetic cannabinoid). The 4F-MDMB-BICA code name used for the substance is derived from its structural features: a methyl 3,3-dimethylbutanoate linked group (MDMB), a 4-fluorobutyl tail (4F and B) attached to the indole nitrogen atom of an indole core (I), and a carboxamide linker (CA).

FIGURE 1

Chemical structures and molecular information of 4F-MDMB-BICA, 4F-MDMB-BINACA, and 5F-MDMB-PICA

4F-MDMB-BICA	4F-MDMB-BINACA	5F-MDMB-PICA
		
Molecular formula: $C_{20}H_{27}FN_2O_3$	Molecular formula: $C_{19}H_{26}FN_3O_3$	Molecular formula: $C_{21}H_{29}FN_2O_3$
Molecular weight: 362.44	Molecular weight: 363.43	Molecular weight: 376.47
Monoisotopic mass: 362.2006	Monoisotopic mass: 363.1958	Monoisotopic mass: 376.2162

Common name:

4F-MDMB-BICA

Systematic (IUPAC) name:

Methyl 2-[[1-(4-fluorobutyl)-1*H*-indole-3-carbonyl]amino]-3,3-dimethylbutanoate

Other chemical names:

Methyl 3,3-dimethyl-2-[1-(4-fluorobutyl)-1*H*-indole-3-carboxamido]butanoate

Methyl 3-methyl-*N*-[1-(4-fluorobutyl)-1*H*-indole-3-carbonyl]valinate

Methyl 3,3-dimethyl-2-[[1-(4-fluorobutyl)-1*H*-indol-3-yl]formamido]butanoate

Methyl *N*-[[1-(4-fluorobutyl)-1*H*-indole-3-yl]carbonyl]-3-methylvalinate

Methyl 2-[1-(4-fluorobutyl)-1*H*-indole-3-carboxamido]-3,3-dimethylbutanoate

Methyl 2-[[1-(4-fluorobutyl)indol-3-yl]formamido]-3,3-dimethylbutanoate

Methyl 2-[[1-(4-fluorobutyl)indole-3-carbonyl]amino]-3,3-dimethyl-butanoate

Methyl *N*-[[1-(4-fluorobutyl)-1*H*-indol-3-yl]carbonyl]-3-methylvalinate

Methyl 2-[[1-(4-fluorobutyl)indol-3-yl]formamido]-3,3-dimethylbutanoate

N-(1-methoxy-3,3-dimethyl-1-oxobutan-2-yl)-1-(4-fluorobutyl)-1*H*-indole-3-carboxamide

Other names:

MDMB-4F-BICA

4F-MDMB-BICA

4F-MDMB-2201

MDMB-4F-BUTICA

4F-MDMB-BUTICA

4-Fluoro MDMB-BICA

4-Fluoro MDMB-BUTICA

4FBC

4FBCA

MDMB-073-F

Street names:

'Bika' (in Hungary, meaning 'bull') (Tihanyi et al., 2020)

At least historically, a common slang name for smoking mixtures containing synthetic cannabinoids in some countries is 'Spice' — which is a reference to the most common brand name used for these types of products when they first appeared on the market. Many other names are now used and depend on the country, region, product type, brand names, and user groups. These include: 'smoking mixtures', 'herbal smoking mixtures', 'herbal incense', 'synthetic cannabis', 'legal weed', and 'K2'. A common name used in Hungary is 'magic tobacco'; in France 'chimique'; in Turkey, 'Bonsai'; whereas in Birmingham, United Kingdom, the name 'Black Mamba' or simply 'Mamba' is used. In one case reported to EMCDDA, a seized smoking mixture branded as a 'legal-high' product called 'Pico Bello' was found to contain 4F-MDMB-BICA.

Smoking mixtures were also found to contain other synthetic cannabinoids (MDMB-4en-PINACA⁽⁷⁾, 5F-MDMB-PICA⁽⁵⁾, and 5F-EMB-PICA⁽⁸⁾). Product names cannot be considered a reliable source of information regarding the actual substances present in such products since the compositions of such products might be subject to significant variations in contents (e.g. Moosmann et al., 2015; Frinculescu et al., 2017). Three seized samples determined to be 4F-MDMB-BICA were labelled incorrectly as '5F-MDMB-2201' (5F-MDMB-PICA; two cases) (EMCDDA, 2020b) and 4F-MDMB-BINACA (one case).

Chemical Abstracts Service (CAS) registry numbers:

Not yet listed (as of 15 Nov 2020)

IUPAC International Chemical Identifier Key (InCHI Key):

QIKHYQCWGUGFBB-UHFFFAOYSA-N

Simplified Molecular-Input Line-Entry System (SMILES):

FCCCCN1C=C(C2=CC=CC=C12)C(=O)NC(C(=O)OC)C(C)(C)C⁽⁹⁾

2.3 Physical properties

In its pure form 4F-MDMB-BICA has been described as a crystalline solid (Cayman Chemical Company, 2020a; Cayman Chemical Company, 2020b). Seized powder samples containing 4F-MDMB-BICA have been described as white, brown-off-white, beige-brown, orange, rose-red crystal-like (EMCDDA, 2020a; EMCDDA, 2020b), and as an orange coloured amorphous solid material (HIFS, 2020). The pure material has been described as a white solid with a melting point of 86–88 °C (Stove and Banister, personal communication)⁽¹⁰⁾. Based on seizures and collected samples reported to the EMCDDA, 4F-MDMB-BICA has been detected in smoking mixtures, powders, paper impregnated with

⁽⁸⁾ 5F-EMB-PICA IUPAC name: ethyl 2-[[1-(5-fluoropentyl)-1H-indole-3-carbonyl]amino]-3-methylbutanoate

⁽⁹⁾ Generated from IUPAC name by OPSIN: Open Parser for Systematic IUPAC nomenclature (<http://opsin.ch.cam.ac.uk>) (Lowe et al., 2011).

⁽¹⁰⁾ Cannaert et al. 2020

the substance (including blotters), liquids, and e-liquids contained in a vape cartridge. In addition, on one occasion, powdered ‘nuggets’ of 4F-MDMB-BICA were found in a mixture with tobacco and on another occasion, 4F-MDMB-BICA was identified in a liquid that was reported to be in a bottle of nail varnish remover (EMCDDA, 2020b).


2.4 Methods and chemical precursors used for the manufacture or extraction

No information was reported by the Member States, Norway, or Turkey about the chemical precursors or manufacturing methods used to make the 4F-MDMB-BICA which has been identified within Europe.

The synthesis of (S)-4F-MDMB-BICA has been described (Stove and Banister, personal communication) ⁽¹⁰⁾ following previously established procedures (Banister et al., 2016; Banister et al., 2019) (Figure 2). Indole (1) undergoes *N*-alkylation with 1-bromo-4-fluorobutane and acylation with trifluoroacetic anhydride to give the 2,2,2-trifluoro-1-[1-(4-fluorobutyl)-1*H*-indol-3-yl]ethanone intermediate (2). Hydrolysis under alkaline conditions produces the carboxylic acid intermediate 1-(4-fluorobutyl)-1*H*-indole-3-carboxylic acid (3). Coupling with methyl *L*-*tert*-leucinate (methyl (2*S*)-2-amino-3,3-dimethylbutanoate) ⁽¹¹⁾ gives (S)-4F-MDMB-BICA (4) (Figure 2).

FIGURE 2

Synthesis route for (S)-4F-MDMB-BICA starting from indole (1)



Note: Stove and Banister, personal communication ⁽¹⁰⁾ (a) (i) NaH, DMF, 1-bromo-4-fluorobutane; 0 °C–rt, 1 h; (ii) (CF₃CO)₂O, 0 °C–rt, 2 h; (b) KOH, MeOH, PhMe, reflux, 2 h; c) methyl *L*-*tert*-leucinate, EDC·HCl, HOBT·H₂O, Et₃N, DMF, rt, 18 h. For the preparation of the (*R*)-enantiomer, the coupling reaction would involve the use of methyl *D*-*tert*-leucinate instead.

2.5 Methods for identification and analysis

Analytical data for 4F-MDMB-BICA and methods for its detection have been published in the scientific literature and public domain (Table 1). The analysis of biological specimen requires sensitive methods of analysis, e.g. liquid chromatography coupled to (tandem)

⁽¹¹⁾ (S)-L-*tert*-Leucine is widely used for the manufacture of antiviral medicines and is produced mainly in China in large quantities. This may explain the choice of this precursor for the synthesis of 4F-MDMB-BICA and other related synthetic cannabinoids that have been reported to the EU Early Warning System.

mass spectrometry approaches (high and low resolution). (*S*)-4F-MDMB-BICA is available as reference material from commercial suppliers. EMCDDA have not yet received any information about the enantiomeric composition of 4F-MDMB-BICA-containing products although the presence of the (*S*)-enantiomer, similar to most other closely related synthetic cannabinoids available on the market, seems likely. However, the presence of the (*R*)-enantiomer in seized samples or the racemic mixture cannot not be excluded in the absence of further information. In some biological specimen, the parent molecule might not always be detectable directly as a consequence of ester hydrolysis which gives rise to the formation of an acidic transformation product ⁽¹²⁾, a phenomenon described for other synthetic cannabinoids with such ester moieties (e.g. Ong et al., 2020). However, the detection of this metabolite/degradation product alone might not be sufficient for unambiguous identification as it might also arise from various other ester and amide analogues (see, for example, Diao and Huestis, 2019).

TABLE 1
Detections and analytical data associated with the detection and chemical analysis of 4F-MDMB-BICA (amongst other substances) available in the scientific literature and public domain

Techniques ^(a)	Comment	Reference
GC-MS; LC-MS	Analysis of seized material	Krotulski et al. (2020)
GC-MS; LC-MS; IR; Raman; NMR	Analysis of herbal mixture and orange solid	ADEBAR Project (2020)
MP; LC-MS; LC-UV; IR; NMR	Analysis of synthesised material	Stove and Banister, personal communication ⁽¹⁰⁾
GC-MS, UV	Analysis of synthetic reference material	Cayman Chemical Company (2020a, 2020c)
GC-MS; IR; NMR	Analysis of orange, amorphous solid	HIFS (2020)
GC-MS; IR; LC-MS; IC; NMR	Analysis of test purchased powder	NFL Ljubljana (2020)
IMS, ESI-MS	Analysis of seized paper impregnated samples in prisons	Norman et al. (2020)

⁽¹²⁾ Ester hydrolysis product IUPAC name: 3,3-dimethyl-2-[[1-(4-fluorobutyl)-1H-indole-3-carbonyl]amino]butanoic acid

(^a) GC: gas chromatography; MS: mass spectrometry; LC: liquid chromatography; IR: infrared spectroscopy; Raman: Raman spectroscopy; NMR: nuclear magnetic resonance spectroscopy; MP: melting point; UV: ultraviolet spectroscopy; IC: ion chromatography; IMS: ion mobility spectrometry; ESI: electrospray ionisation. LC-MS and ESI-MS: might involve single, tandem, low, or high-resolution methods of analysis.

2.6 Dosage regimens

Information on the dose and dosage regimens (¹³) for 4F-MDMB-BICA is limited. Products containing synthetic cannabinoids such as 4F-MDMB-BICA rarely state the correct ingredients and concentrations, as such, people who use such products will be unaware that they are using this substance and will be unable to obtain accurate dosage information.

In addition, in respect to smoking mixtures, the process for mixing the synthetic cannabinoids with the plant material to make the smoking mixture can lead to dangerous amounts of the substances in the products. This is because producers have to guess the amount of substances to be added, while the mixing process makes it difficult to dilute them sufficiently and distribute them consistently throughout the plant material. This can result both in products that contain toxic amounts of the substances in general (Ernst et al. 2017; Frinculescu et al. 2017; Langer et al. 2014; Langer et al. 2016), as well as in products where the solid particles of synthetic cannabinoids are clumped together, forming highly concentrated pockets within the plant material (Frinculescu et al. 2016; Moosmann et al. 2015; Schäper et al. 2016). In fact, in the latter case, simply tapping a packet containing a smoking mixture can dislodge the substances from the plant material. In addition, paper (such as blotters and cards) impregnated with synthetic cannabinoids can pose a similar high risk of poisoning because the amount of synthetic cannabinoid can be unevenly distributed in different parts of the paper, sometimes forming highly concentrated sections on the paper (Norman, et al., 2020). These issues are made worse because the products are smoked or vaped, allowing the substances to be rapidly absorbed into the bloodstream and to reach the central nervous system and other parts of the body to cause their effects. Accounts from patients and people who witness poisonings suggest that in some cases a small number of puffs from a cigarette (“joint”) have been sufficient to cause severe and fatal poisoning.

Together, these factors, coupled to the typically high potency of synthetic cannabinoids, makes it difficult for users to control the dose that they are exposed to. This can lead them to unintentionally administer a toxic dose.

Reports posted on Internet forums that involve information of dosage regimens of 4F-MDMB-BICA are currently very limited. 4F-MDMB-BICA can be inhaled by smoking and it

(¹³) Dosage regimen: is information on the formulation (dosage form), route of exposure, as well as the schedule of doses of a new psychoactive substance, including the amount taken each time, time between doses, and the duration of use.

is expected that similar to related synthetic cannabinoids, that 4F-MDMB-BICA might also be inhaled by vaporising e-liquid solutions ('vaping'), for example by using electronic cigarettes, and administered orally or sublingually (Reddit, 2020).

The concentration of 4F-MDMB-BICA in products seized by law enforcement or from collected samples in Europe has not been reported ⁽¹⁴⁾. The composition of products is likely to vary over time and place, as well as based on the specific location in the drug supply chain in which the sample is obtained from (for example, from the manufacturer, wholesaler, retailer, or at street-level markets).

Information involving the analysis of seized and collected samples reported to the EMCDDA notes that 4F-MDMB-BICA has been encountered in the form of smoking mixtures, powders, papers (including blotters) impregnated with the substance, and liquids (EMCDDA, 2020b).

Papers, including blotters and cards, impregnated with 4F-MDMB-BICA were seized in prisons and other custodial settings in Cyprus, Hungary, Lithuania, and the United Kingdom (EMCDDA, 2020b). In the latter case, seizures were made Scottish prisons during 2020, with the first seizure made in May 2020 (McKenzie, 2020; Norman et al., 2020).

Drug-checking services operating in Switzerland have reported two cannabis samples adulterated with 4F-MDMB-BICA. In addition to cannabidiol and traces of THC ⁽¹⁾, one of the samples revealed the presence of 4F-MDMB-BICA and MDMB-4en-PINACA ⁽⁷⁾, whereas the other sample contained 4F-MDMB-BICA, 5F-MDMB-PICA ⁽⁵⁾ and MDMB-4en-PINACA ⁽⁷⁾ (Erowid, 2020; Rave it Safe, 2020; Saferparty.ch, 2020).

In the United States of America (USA), the Centre for Forensic Science Research and Education (CFSRE) reported its first identification of 4F-MDMB-BICA in July 2020. The report was related to the analysis plant-like material seized in May 2020 (Krotulski et al., 2020).

Formal epidemiological studies have not been performed to examine the use and patterns of use of 4F-MDMB-BICA, however in many cases these are likely to share some similarities with other synthetic cannabinoids. Anecdotal reports on internet drug discussion forums and related websites from people who used a substance believed to be 4F-MDMB-BICA are very limited. One report involving the inhalation ('vaping') of pure 4F-MDMB-BICA powder, estimated to represent a dose of approximately 50 µg, was considered by the user to be intoxicating (Reddit, 2020). However, it is not possible to currently discern typical dosage regimens. These also depend on the tolerance of the user, the use of other drugs, and the desired effects. Furthermore, the purity, amount and/or composition of the

⁽¹⁴⁾ Slovenia reported a test-purchase of 4F-MDMB-BICA made by the EU-funded project RESPONSE; the substance was identified in 5 grams of beige-brown powder contained in a zip-lock plastic bag. The purity of the sample was over 95%.

substance ingested are not typically known by the user. In addition, the actual composition of product containing the substance may differ over time and place.

3. Legitimate use

3.1 Summary

Based on the available information, it appears that 4F-MDMB-BICA is not an active substance in a medicinal product for human use or in a veterinary medicinal product in Europe.

However, although highly unlikely, the use of 4F-MDMB-BICA as an active substance in medicinal products prepared extemporaneously or in investigational medicinal products cannot be excluded in some Member States (EMCDDA, 2020b). There is currently no information that suggests 4F-MDMB-BICA is used for legitimate purposes other than research or forensic applications in Europe.

3.2 Medical use

Based on information from the European Medicines Agency for the initial report (EMCDDA, 2020b), it appears that 4F-MDMB-BICA is not an active substance in:

- a medicinal product for human use or in a veterinary medicinal product that has obtained a marketing authorisation in accordance with Directive 2001/83/ EC of the European Parliament and of the Council, Directive 2001/82/EC of the European Parliament and of the Council or Regulation (EC) No 726/2004 of the European Parliament and of the Council;
- a medicinal product for human use or in a veterinary medicinal product that is the subject of an application for a marketing authorisation;
- a medicinal product for human use or in a veterinary medicinal product whose marketing authorisation has been suspended by the competent authority.

In addition, it appears that 4F-MDMB-BICA is not an active substance in the following, although the information, especially in relation to use in extemporaneously prepared products, is unknown in some cases:

- an unauthorised medicinal product for human use in accordance with Article 5 of Directive 2001/83/ EC or in a veterinary medicinal product prepared extemporaneously by a person authorised to do so under national law in accordance with point (c) of Article 10(1) of Directive 2001/82/EC;
- an investigational medicinal product as defined in point (d) of Article 2 of Directive 2001/20/EC of the European Parliament and of the Council.

3.3 Industrial, commercial, and scientific use

4F-MDMB-BICA is used as an analytical reference material in clinical and forensic casework as well as scientific research. There is currently no information that suggests 4F-MDMB-BICA is used for other legitimate purposes.

As part of the initial report process, the European Chemical Agency (ECHA) and European Food Standard Authority (EFSA) reported to the EMCDDA that 4F-MDMB-BICA did not retrieve any results in their information systems (EMCDDA, 2020b).

4. Pharmacological and toxicological properties

4.1 Summary

(S)-4F-MDMB-BICA has been shown to act as a potent, full agonist at the cannabinoid type 1 (CB₁) receptor when investigated under *in vitro* conditions. When studied under identical assay conditions, the homologue (S)-5F-MDMB-PICA⁽⁵⁾ was found to be ~37- and ~57-times more potent. The indazole counterpart (S)-4F-MDMB-BINACA⁽⁴⁾ was determined to be ~16- and ~44 times more potent than (S)-4F-MDMB-BICA. A comparison with another synthetic cannabinoid under international control (JWH-018, ⁽¹⁵⁾) revealed that it activated the CB₁ receptor with comparable potency. Information on the pharmacokinetics of 4F-MDMB-BICA could not be identified but it is expected to be comparable to closely related substances such as 5F-MDMB-PICA and 4F-MDMB-BINACA. No studies were identified that have investigated the pharmacodynamics of 4F-MDMB-BICA on pharmacological targets other than the CB₁ receptor.

Although not formally studied, the psychological and behavioural effects of 4F-MDMB-BICA are likely to share similarities with those commonly reported for other synthetic cannabinoids, including: relaxation, euphoria, lethargy, confusion, anxiety, fear, distorted perception of time, depersonalisation, hallucinations, paranoia, as well as dry mouth, bloodshot eyes, cardiovascular effects, nausea, vomiting and impaired motor performance.

In vivo studies and information on toxicological properties of 4F-MDMB-BICA could not be identified. Compared to cannabis, severe and fatal poisoning appears to be more common with synthetic cannabinoids. Poisoning may include rapid loss of consciousness/coma, cardiovascular effects (such as hypertension, tachycardia, bradycardia, chest pain, myocardial infarction, and stroke), seizures and convulsions, vomiting (including hyperemesis), delirium, agitation, psychosis, and, aggressive and violent behaviour.

⁽¹⁵⁾ JWH-018 IUPAC name: (naphthalen-1-yl)(1-pentyl-1*H*-indol-3-yl)methanone

Sudden death has also been reported. There is no known antidote to poisoning caused by synthetic cannabinoids.

The information shared online by people who used a substance they believed to be 4F-MDMB-BICA is very limited. Reported adverse effects included anxiety, visual alterations, loss of consciousness, increased heart rate, and derealisation. 4F-MDMB-BICA was considered a potent substance when inhaled by 'vaping', with effects lasting around 40–60 min, according to one anecdotal report; the perceived high potency of 4F-MDMB-BICA required adjustments to be made relating to the number and extent of inhalations ('hits'). It should be noted that the assessment of such reports is problematic not least because typically users cannot confirm the substance they were actually using or the amount used. In general, given the difficulties of collecting accurate self-reported data, it should be interpreted with caution.

The abuse liability and dependence producing potential of 4F-MDMB-BICA have not been studied. However, it has been suggested that consumption of synthetic cannabinoids can produce tolerance and withdrawal-like symptoms when use is discontinued following a regular use.

4.2 Pharmacodynamics

4.2.1 *In vitro* data

Though limited, currently available information from *in vitro* studies suggests that 4F-MDMB-BICA binds to and activates the cannabinoids type 1 (CB₁) receptor as a full agonist (Table 2). Compared to another synthetic cannabinoids under international control (JWH-018) ⁽¹⁴⁾ used as a positive control, its efficacy was found to increase to $E_{\max} = 253\%$ (Stove and Banister, personal communication) ⁽¹⁰⁾. The potency of 4F-MDMB-BICA ($EC_{50} = 121$ nM; ⁽¹⁶⁾) was considerable although it dropped by a factor of ~16 and ~44 compared to its indazole counterparts 4F-MDMB-BINACA ⁽⁴⁾ (Table 2). Similarly, the homologue 5F-MDMB-PICA ⁽⁵⁾ was also shown to be ~37- and ~57-times more potent than 4F-MDMB-BICA. Another comparison with JWH-018 revealed that it activated the CB₁ receptor with comparable potency (Persson et al., 2020) (Table 2).

⁽¹⁶⁾ EC_{50} represents the half maximal effective concentration for a given substance.

TABLE 2

***In vitro* activation data at the hCB₁ receptor reported for enantiopure 4F-MDMB-BICA in comparison with 4F-MDMB-BINACA and 5F-MDMB-PICA under identical assay conditions ^a**

Compound	EC ₅₀ (nM)	E _{max} (%)	Reference
4F-MDMB-BICA	121	253	(Stove and Banister, personal communication) ⁽¹⁰⁾ .
4F-MDMB-BINACA	7.39	378	(Stove and Banister, personal communication) ⁽¹⁰⁾ .
	2.78	255	Antonides et al. (2020)
5F-MDMB-PICA	3.26	331	Noble et al. (2019)
	2.13	289	Antonides et al. (2020)
4F-MDMB-BICA	37.7	129	Persson et al. (2020) ^b
^a HEK cells; β-arrestin 2 recruitment assay; relative to JWH-018 (E _{max} = 100%); EC ₅₀ = 14,2 nM; data are for the (S)-enantiomers. Reductions in potency were determined for the (R)-enantiomers: 4F-MDMB-BINACA (EC ₅₀ = 1076 nM; E _{max} = 128%); 5F-MDMB-PICA (EC ₅₀ = 224 nM; E _{max} = 121%) (Antonides et al. 2020). ^b Aquerin base system; CB ₁ receptor expressed in CHO cells; relative to JWH-018 (E _{max} = 100%); EC ₅₀ = 51.9 nM.			

It is not known whether 4F-MDMB-BICA affects other pharmacological targets, such as receptors, enzymes or transport processes.

4.2.2 *In vivo* data

Information on the *in vivo* effects of 4F-MDMB-BICA could not be identified. Based on the available information obtained from investigations carried out so far *in vitro* (Table 2), it is likely that 4F-MDMB-BICA will also share similar properties compared to other synthetic cannabinoids. For example, cannabimimetic (i.e. THC-like) effects expected to be induced by 4F-MDMB-BICA in mice may include hypolocomotion, antinociception, hypothermia, and catalepsy (Wiley et al., 2017) and THC-like discriminative stimulus effects (Wiley et al., 2018; Wiley et al., 2019). However, the reported comparatively low potency *in vitro* of 4F-MDMB-BICA (EC₅₀ = 121 nM; Table 2) alone fails to explain the local outbreak of serious adverse events, including death cases, where post-mortem analysis detected (see also Section 6).

4.3 Psychological and behavioural effects

Information on the study of psychological and behavioural effects of 4F-MDMB-BICA in humans could not be identified. Based on the limited information on the pharmacological

properties of 4F-MDMB-BICA, as well information from previous observations involving closely related synthetic cannabinoids such as 4F-MDMB-BINACA⁽⁴⁾ and 5F-MDMB-PICA⁽⁵⁾ (WHO, 2019b; WHO, 2019a), it is likely that the effects of 4F-MDMB-BICA share some similarities with those commonly reported for other synthetic cannabinoids, including: relaxation, euphoria, lethargy, confusion, anxiety, fear, distorted perception of time, depersonalisation, hallucinations, paranoid delusions, as well as dry mouth, bloodshot eyes, cardiovascular effects, nausea, vomiting and impaired motor performance. These dose-dependent effects appear to be much more pronounced and severe when compared to cannabis (Ford et al., 2017; Zaurava et al., 2016). In addition, psychotic episodes, confusion, paranoia, as well as aggressive and violent behaviour, have also been reported (EMCDDA, 2018; Yalçın et al., 2018). Effects reported by people who used a substance believed to be 4F-MDMB-BICA included anxiety, visual alterations, loss of consciousness, and derealisation (Reddit, 2020).

A case series of three individuals suspected of committing a road traffic offence and with confirmed exposure to the homologue 5F-MDMB-PICA⁽⁵⁾ but no other toxicological findings noted the following physical effects: balance deficiencies and ocular effects such as reddened conjunctivae, glassy eyes and delayed or unresponsive pupil light reactions. Observed mental and behavioural effects were predominantly changing moods, aggression, confusion, erratic behaviour, mental leaps, disorientation, slowed reaction, and slurred speech (Kleis et al., 2020).

4.4 Safety pharmacology

Detailed information on the safety pharmacology (ICH, 2000) of 4F-MDMB-BICA could not be identified. However, the available data suggest that this substance is a reasonably potent, full CB₁ receptor agonist *in vitro*. Based on the currently available information on the pharmacological properties of 4F-MDMB-BICA, as well as information from previous observations involving closely related synthetic cannabinoids such as 4F-MDMB-BINACA⁽⁴⁾ and 5F-MDMB-PICA⁽⁵⁾ (WHO, 2019b; WHO, 2019a), adverse effects from overdosing 4F-MDMB-BICA might include gastrointestinal (e.g. nausea, vomiting (including hyperemesis)), neurological (e.g. hallucination, agitation, anxiety, paranoia, confusion, delusions, catatonia, lethargy, psychosis (including susceptible individuals) and severe central nervous system depression (such as rapid loss of consciousness/coma)), cardiovascular (e.g. tachycardia, hypertension, acute myocardial infarction and sudden cardiac death) and renal (e.g. acute kidney failure) clinical features (Ford et al., 2017; Hermanns-Clausen et al., 2013; Ozturk et al., 2019; Pacher et al., 2018; Tait et al., 2016). These effects appear to be much more pronounced and severe when compared to cannabis (Ford et al., 2017; Zaurava et al., 2016). Effects reported by people who used a substance believed to be 4F-MDMB-BICA included anxiety, loss of consciousness, and visual alterations (Reddit, 2020).

4.5 Pharmacokinetics

Information on the biotransformation and pharmacokinetic parameters of 4F-MDMB-BICA could not be identified. The structural similarity to 4F-MDMB-BINACA⁽⁴⁾ suggests that similar metabolic conversions might be involved, for example ester hydrolysis (+ detection of glucuronidation products in urine), oxidative defluorination, formation of butanoic acid substituent (tail), hydroxylations of aromatic and alkyl moieties, dehydrogenation, lactone formation, *N*-dealkylation and a combination of those metabolic reactions (Diao and Huestis, 2019; Haschimi et al., 2019; Krotulski et al., 2019; Wagmann et al., 2020). Correspondingly, the metabolic steps thought to be involved in humans following ingestion of the homologue 5F-MDMB-PICA⁽⁵⁾ (e.g. mono-hydroxylation, oxidative defluorination, dehydrogenation, amide, and ester hydrolysis, as well as combinations of these metabolic modifications) (Kleis et al., 2020; Mogler et al., 2018) are likely to apply to 4F-MDMB-BICA as well.

The pharmacological activity, if any, of the possible metabolites of 4F-MDMB-BICA is not known.

Information about the duration of effects recorded during human studies could not be identified. An anecdotal report from a person who used a substance believed to be 4F-MDMB-BICA suggested a duration of effects around 40–60 min when inhaled in the form of a 'c-liquid'; the perceived high potency of 4F-MDMB-BICA required adjustments to be made relating to the number and extent of inhalations ('hits') (Reddit, 2020).

4.6 Toxicology

Information on the toxicological properties (including pre-clinical safety data) of 4F-MDMB-BICA could not be identified.

Though relevant information is lacking, the involvement of other, non-cannabinoid toxicological targets or unexpected drug-drug interactions in the overall pharmacotoxicological effects of 4F-MDMB-BICA cannot be excluded.

There is no known antidote to poisoning caused by synthetic cannabinoids. Treatment in poisoning cases should be symptomatic.

4.7 Abuse liability and dependence producing potential

Information on the abuse liability and dependence producing potential of 4F-MDMB-BICA could not be identified. It has been suggested that consumption of synthetic cannabinoids can produce tolerance and withdrawal-like symptoms when use is discontinued following a regular use. Withdrawal-like symptoms following cessation of synthetic cannabinoids have been described in the literature. These include: anxiety, unstable mood, crying fits, feeling of inner emptiness, spatial disorientation, hyperacusis (increased sensitivity to ordinary

environmental sounds), somatic pain, shortness of breath, hyperventilation, intense sweating and sensations of motor and inner restlessness (Cooper, 2016; Macfarlane and Christie, 2015; Van Hout and Hearne, 2017; Zimmermann et al., 2009). Given what is currently known about the pharmacology of synthetic cannabinoids in general, including the closely related 5F-MDMB-PINACA ⁽⁶⁾ (and some similarities to THC), it is reasonable to consider that 4F-MDMB-BICA has a potential for abuse and dependence (EMCDDA, 2018).

5. Extent and patterns of use, availability, and potential for diffusion

5.1 Summary

There is limited information on the extent and patterns of use, availability, and potential for diffusion of 4F-MDMB-BICA in Europe.

4F-MDMB-BICA has been available on the drug market in Europe since at least March 2020, when it was seized by customs in Belgium. As of November 2020, 4F-MDMB-BICA has been identified in twelve Member States; 111 seizures have been reported, which include 5.6 kg of powder and 0.6 kg of smoking mixtures. Of particular note are four large scale seizures of 4F-MDMB-BICA powder reported by Belgian customs and eleven seizures that occurred in prisons. The most recent identifications of 4F-MDMB-BICA reported to the EMCDDA are from seizures made by police in Cyprus and customs in Finland in September 2020.

The available information suggests that 4F-MDMB-BICA is manufactured by chemical companies based in China. It is imported into Europe as bulk powders and then sold and distributed in wholesale and retail amounts within Europe either as a powder for processing into products or finished consumer products. There are three main types of products containing 4F-MDMB-BICA that are available on the drug market:

- smoking mixtures, where 4F-MDMB-BICA is mixed with herbal material or tobacco that is then smoked or inhaled, for example using a vaporiser (similar to herbal cannabis, the mixture is usually prepared for smoking as a hand-rolled cigarette ('joint'));
- e-liquids, where a solution of 4F-MDMB-BICA is prepared by mixing it with a solvent, which is then inhaled using an e-cigarette; and
- impregnated on to paper which can then be smoked or vaped. This is a commonly used approach to smuggle synthetic cannabinoids into prison in some countries.

To a lesser extent, people who are using these substances may also prepare their own products using powdered 4F-MDMB-BICA purchased from a vendor or dealer.

Although 4F-MDMB-BICA may be deliberately sought after by some users, in most cases, such as those that purchase it at street-level and/or in prison, they are likely to be unaware that they are using the substance which presents an inherent risk to the individuals.

As 4F-MDMB-BICA has only recently emerged on the drug market in Europe, it is important to note that its presence on the market and as the cause of serious adverse events (such as from acute poisonings presenting to hospital emergency rooms and medico-legal death investigations) may be undetected since the substance is not routinely screened for in some laboratories. It is also important to note that, in some settings, the on-going COVID-19 pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (ECDC, 2020; EMCDDA, 2020e; WHO, 2020b) may have reduced the capacity of early warning systems, including forensic science and toxicology laboratories, to detect and report events involving 4F-MDMB-BICA.

The effect of the on-going COVID-19 pandemic (ECDD, 2020; EMCDDA, 2020e; WHO, 2020b) on the manufacture, trafficking, distribution, and use of 4F-MDMB-BICA is currently unknown. However, seizures of bulk powders by European national customs agencies during the pandemic suggests that it continues to be imported into and distributed within Europe. It is conceivable that should there be a reduced availability of cannabis and other synthetic cannabinoids in Europe, criminal groups as well as people who use drugs, may use a range of replacement substances, including 4F-MDMB-BICA.

5.2 Information from seizures

Law enforcement seizures of 4F-MDMB-BICA have been reported by 12 Member States: Hungary (72 seizures), the United Kingdom (17), Belgium (4), Slovenia (4), Cyprus (3), Finland (3), Germany (2), Lithuania (2), Croatia (1), Poland (1), Italy (1), and Sweden (1).

In total, 111 seizures were reported. These included: 8 seizures by customs and 103 seizures by police; 11 of the police seizures occurred in prisons. Where reported, seizures took place between March and September 2020.

Seizures included smoking mixtures (32 cases), powders (20), blotters and other types of paper impregnated with the substance (7), and liquids (3). For 49 of the seizures reported by Hungary no details were provided.

5.2.1 Customs seizures

A total of 8 seizures were made by customs and amounted to 5.58 kg. These were reported by: Belgium (4), Finland (3), and Sweden (1). All the seizures were in powder form, and occurred between March and September 2020.

The seizures reported by Belgium accounted for 99.9% of the powders seized by customs (3 kg, 1.5 kg, and 2 seizures of approximately 0.5 kg each). The seizure that led to the formal notification of 4F-MDMB-BICA, made at Liège Airport, was reported as a case of

large-scale international trafficking; the parcel originated from China and was *en route* to the Netherlands. The destination for all the seizures reported by Belgium was the Netherlands.

The three seizures reported by Finland originated from the Netherlands (2) and Spain (1). One of the seizures was labelled as '5F-MDMB-2201'.

Sweden reported a seizure of 4F-MDMB-BICA powder amounting to 9.82 g in a package labelled '5F-MDMB-2201'.

No other substances were typically reported in seizures made by customs. In one seizure reported by Belgium, the precursor ethylamine (ethanamine) was identified at approximately 4% (w/w %) along with other minor impurities (section 3.2.3).

The available information suggests that at least some powders of 4F-MDMB-BICA are sourced from China and imported to Europe via Belgium to the Netherlands.

5.2.2 Police seizures

A total of 103 seizures made by police were reported by Hungary (72 seizures), the United Kingdom (17), Slovenia (4), Cyprus (3), Germany (2), Lithuania (2), Croatia (1), Poland (1), and Italy (1). These seizures occurred between April and September 2020.

Out of the 103 police seizures, 11 seizures occurred in prisons, and were reported by Slovenia (4), the United Kingdom (3), Lithuania (2), Cyprus (1), and Hungary (1).

4F-MDMB-BICA was detected in smoking mixtures, powders, paper impregnated with the substance (including blotters), and liquids. All the seizures of impregnated papers and blotters occurred in prisons. A summary is provided below.

Smoking mixtures

In total, 32 seizures of smoking mixtures containing 4F-MDMB-BICA were reported by Police. These amounted to 612.66 g and were reported by Hungary (12 cases), the United Kingdom (12), Slovenia (4), Cyprus (2), Croatia (1), and Germany (1).

There is no information on the concentration of 4F-MDMB-BICA in the smoking mixtures. In 15 cases, no substances other than 4F-MDMB-BICA were reported. In the remaining 17 cases, alongside the identification of 4F-MDMB-BICA, 1 other synthetic cannabinoid (10 cases), 2 (2), 3 (3), 4 (1) and 7 other cannabinoids (1) were also identified.

All four seizures reported by Slovenia occurred in prisons. The samples also contained MDMB-4en-PINACA, 5F-MDMB-PICA and 5F-EMB-PICA. One of the seizures contained a total of 8 different synthetic cannabinoids.

In one case reported by Germany, the mixtures were found in a branded 'legal-high' product ('Pico Bello'); in another case the mixture was found in aluminium bag.

Powders

In total, 12 seizures of powder containing 4F-MDMB-BICA were reported by 4 Member States: Hungary (9), Germany (1), Poland (1) and Italy (1). The seizures reported by Germany, Poland, and Italy amounted to 12.78 grams.

Powders were described as white, off-white, brown, and orange. Appearance as rose-red crystals was also reported. No other substances were reported to be detected in the powders.

In one case reported by Hungary, powder 'nuggets' were found in a mixture with tobacco at the scene of a death. It is not clear whether the mixture was supplied as such to the deceased or whether it was homemade.

Impregnated papers, including blotters

In total, 7 seizures of paper impregnated with 4F-MDMB-BICA were reported to the EMCDDA. These were reported by the United Kingdom (3), Lithuania (2), Cyprus (1) and Hungary (1). All the seizures occurred in prisons and other custodial settings.

Other synthetic cannabinoids were detected in 3 of the seizures, predominantly MDMB-4en-PINACA⁽⁷⁾ (identified in 3 cases), and 5F-MDMB-PICA (2)⁽⁵⁾.

In the case reported by Cyprus, 14 impregnated sheets of A4 sized paper which had been concealed inside a television were seized in a delivery of a package to a prison.

Liquids

A total of 3 seizures containing 4F-MDMB-BICA in liquid form were reported by two Member States: the United Kingdom (2) and Hungary (1).

In the 2 seizures reported by the United Kingdom, 4F-MDMB-BICA was detected in an e-liquid contained within a vaping cartridge. The seizures were of 0.8 and 563 mL. The seizure of 0.8 mL also contained 4F-MDMB-BINACA⁽⁴⁾.

In the seizure reported by Hungary, 4F-MDMB-BICA was identified in a liquid that was reported to be in a bottle of nail varnish remover.

Other

For 49 seizures reported by Hungary no details were provided.

5.3 Information from collected samples

Slovenia reported a test-purchase of 4F-MDMB-BICA made by the EU-funded project RESPONSE; the substance was identified in 5 grams of beige-brown powder contained in a zip-lock plastic bag. The purity of the sample was over 95%.

5.4 Information from biological samples

Serious adverse events with confirmed exposure to 4F-MDMB-BICA from biological samples are discussed in section 6.2.12 and 6.2.2.

Hungary reported 126 cases where exposure to 4F-MDMB-BICA was analytically confirmed in biological samples. All detections were reported as cases due to police arrest. It was reported that in the majority of the cases other substances, mostly synthetic cannabinoids, in particular 5F-MDMB-PICA ⁽⁵⁾ were also identified. Where reported, the cases occurred between May and August 2020 (71 cases).

In addition to information from biological samples reported by the Member States, Table 3 shows the number of identifications of 4F-MDMB-BICA in authentic urine samples analysed by the Institute of Forensic Medicine, Medical Centre, University of Freiburg, Germany, between the third quarter of 2019 and the third quarter of 2020. As can be seen, 4F-MDMB-BICA has only recently been detected in biological samples, i.e. from the second quarter of 2020 onwards. These detections predominantly reflected results from routine screenings involving abstinence control cases within correctional and psychiatric facilities but not poisoning cases.

TABLE 3

Detections of 4F-MDMB-BICA in authentic urine samples at the Institute of Forensic Medicine, Medical Centre, University of Freiburg, Germany ^a

	Q3 2019	Q4 2019	Q1 2020	Q2 2020	Q3 2020	Q4 2020 (until 30 Nov)
Number of samples	1720	1027	1062	873	1123	823
Number of samples positive for synthetic cannabinoids	227 (13%)	239 (23%)	235 (22%)	198 (23%)	268 (24%)	277 (34%)
Number of samples positive for 4F-MDMB-BICA	0	0	0	1 (0.5%)	35 (13%)	53 (19%)
^a Courtesy of Prof. Volker Auwärter						

6. Health risks

6.1 Summary

Data from studies in animals or humans featuring the acute and chronic health effects of 4F-MDMB-BICA use could not be identified. However, it appears likely that the clinical features of poisonings caused by 4F-MDMB-BICA will be similar to those reported from other synthetic cannabinoids resulting in gastrointestinal, neurological, cardiovascular, and renal clinical features. These effects appear to be much more pronounced and severe when compared to cannabis. Similar to other synthetic cannabinoids, the use of 4F-MDMB-BICA with other drugs, especially central nervous system depressants (such as alcohol, opiates/opioids, and sedative/hypnotics) is likely to increase the risk of life-threatening poisoning.

A total of 21 deaths with confirmed exposure to 4F-MDMB-BICA have been reported to the EMCDDA by Hungary. The deaths occurred between May and August 2020. It was reported that in some of the deaths other synthetic cannabinoids, particularly 5F-MDMB-PICA⁽⁵⁾ were detected in biological samples. Reported ante-mortem symptoms and clinical features included chest pain, respiratory problems, tremor, and seizures.

A total of five acute poisonings with confirmed exposure to 4F-MDMB-BICA have been reported to the EMCDDA by the United Kingdom. All the cases included clinical features of poisoning similar to those reported for synthetic cannabinoids. In all cases other substances were identified. In all of the cases, the poisoning was considered life threatening and required hospitalisation of the patient.

There is no information on the chronic health effects of 4F-MDMB-BICA, including abuse liability and dependence production potential. The chronic health risks might share some similarities to those seen with other synthetic cannabinoids. This may include dependence.

6.2 Acute health effects

Specific information about 4F-MDMB-BICA could not be identified. Based on the currently available information on the pharmacological properties of 4F-MDMB-BICA and other closely related synthetic cannabinoids such as 4F-MDMB-BINACA⁽⁴⁾ and 5F-MDMB-PICA⁽⁵⁾ (WHO, 2019b; WHO, 2019a), adverse effects from poisoning with 4F-MDMB-BICA might include gastrointestinal (e.g. nausea and vomiting (including hyperemesis)), neurological (e.g. hallucination, agitation, anxiety, paranoia, confusion, delusions, catatonia, lethargy, psychosis (including susceptible individuals) and severe central nervous system depression (such as rapid loss of consciousness/coma)), cardiovascular (e.g. tachycardia, hypertension, acute myocardial infarction and sudden cardiac death) and renal (e.g. acute kidney failure) clinical features (Ford et al., 2017; Hermanns-Clausen et al., 2013; Ozturk et al., 2019; Pacher et al., 2018; Tait et al., 2016). These effects appear to be much more pronounced and severe when compared to cannabis (Ford et al., 2017;

Zaurova et al., 2016). Effects reported by people who used a substance they believed to be 4F-MDMB-BICA included anxiety, loss of consciousness, visual alterations. In one case, ‘vaping’ pure powder (approximately 50 µg with no tolerance) was considered ‘too much’, with effects including derealisation and an increase in heart rate from 70 to 120 beats per minute (Reddit, 2020).

As discussed in section 2.6, due to the typically high potency of synthetic cannabinoids and inadvertent high dose users may be exposed to from products, it is difficult for users to control the dose that they are exposed to. This can lead them to unintentionally administer a toxic dose.

Some individuals may use 4F-MDMB-BICA in combination with other drugs (either intentionally or unintentionally) and are unlikely to be aware of the substance(s) being ingested and doses used (by whatever route). Similar to other synthetic cannabinoids, the use of 4F-MDMB-BICA with other drugs, especially central nervous system depressants (such as alcohol, opioids, and sedative/hypnotics) is likely to increase the risk of life-threatening poisoning.

Some of the features of poisoning reported for synthetic cannabinoids — particularly loss of consciousness, respiratory depression, and behavioural effects — may place users at additional risks, such as choking on/aspirating vomit, drowning, falling, hypothermia as a result of falling unconscious outside in cold weather, and self-inflicted violence/injury (e.g. EMCDDA, 2017; Tait et al., 2016; Yeter, 2017).

6.2.1 Acute poisonings

Acute poisoning reported by the Member States

A total of five acute non-fatal poisonings with confirmed exposure to 4F-MDMB-BICA were reported to the EMCDDA by the United Kingdom. All cases occurred between June and July 2020. Of the cases, four were male and one was female. The males were aged between 27 and 53 (mean 38; median 36). The female was 31 years old.

All cases included clinical features of poisoning similar to those reported for synthetic cannabinoids, such as confusion, tachycardia, respiratory insufficiency, reduced conscious level, abnormal sweating, and agitation. However, in all cases other substances were also identified in the biological samples taken from the patients, including one or more other synthetic cannabinoid, which may account, at least in part, for the observed effects. Other substances identified in the patients, include:

- other synthetic cannabinoids: MDMB-4en-PINACA (in all cases), 5F-EMB-PICA ⁽⁸⁾ (3 cases), 4F-MDMB-BINACA ⁽⁴⁾ (1 case), AB-FUBINACA ⁽¹⁷⁾ (1 case);

⁽¹⁷⁾ AB-FUBINACA IUPAC name: *N*-[1-amino-3-methyl-1-oxobutan-2-yl]-1-[(4-fluorophenyl)methyl]-1*H*-indazole-3-carboxamide

- benzodiazepines: diazepam (in all cases), flubromazolam (3 cases), etizolam (2 cases), temazepam (2 cases), flualprazolam (1 case), oxazepam (1 case);
- opioids: methadone (in all cases), morphine (3 cases), codeine (3 cases);
- other drugs: pregabalin (4 cases), cocaine (3 cases), THC (3 cases), ketamine (1 case)

In all cases the poisoning was considered to be life-threatening and required hospitalisation of the patient.

Acute poisonings identified from other sources

Information about acute poisoning associated with 4F-MDMB-BICA resulting in non-fatal poisonings from other sources could not be identified.

6.2.2 Deaths

Deaths reported in Europe

A total of 21 deaths with confirmed exposure to 4F-MDMB-BICA were reported to the EMCDDA by Hungary. The cases occurred between May and August 2020. Further details are available on 20 cases and are summarised below.

Of the 20 death cases, all involved males aged between 19 and 42 (mean 28.5; median 28). In 19 cases other substances were identified, including:

- other synthetic cannabinoids: 5F-MDMB-PICA (10 cases); MDMB-4en-PINACA (8 cases);
- benzodiazepines: alprazolam (2 cases); clonazepam metabolite (1 case), midazolam metabolite (1 case);
- other drugs and alcohol: THC (3 cases); alcohol (3 cases); ethylhexedrone (3 cases); ethylheptedrone (2 cases); MDMA (2 cases); ketamine (1 case); carbamazepine (1 case); clomipramine (1 case); tiapride (1 case).

Reported ante-mortem symptoms and clinical features included loss of consciousness, chest pain, respiratory problems, tremor, seizures, somnolence, aggressive behaviour, and foaming at the mouth. Three of the cases were found dead. At least some of the individuals were known drug users. One case involved prisoner and one case a person experiencing homelessness.

A cause of death was reported in 19 cases. The reported causes of death were: cardiac arrest due to substance overdose (7 cases; 37%), acute heart failure (7 cases; 37%), traumatic shock (2 cases; 11%), strangulation (1 case; 5%), brain oedema (1 case; 5%), and asphyxiation following aspirating vomit (1 case; 5%).

In some cases, 4F-MDMB-BICA appears to be supplied to people who are using these substances in a mixture with one or more other synthetic cannabinoids, including 5F-MDMB-PICA and MDMB-4en-PINACA (7) (also subject to an EMCDDA initial report (EMCDDA, 2020c)). It is unknown whether producers add these substances deliberately or accidentally. In addition, it is unknown what effect such mixtures may have in humans.

Evaluating the toxicological significance of synthetic cannabinoids involved in death cases requires a case-by-case approach. This has been recommended to include evaluations of patterns of use (e.g. occasional versus chronic) and tolerance, but also a multi-disciplinary evaluation of clinical, circumstantial, toxicological, and autptic data (Giorgetti et al., 2020).

Deaths identified from other sources

Information about deaths associated with 4F-MDMB-BICA from other sources could not be identified.

6.2.3 Driving and operating machinery under influence

Specific information related to 4F-MDMB-BICA could not be identified. However, driving while under the influence of synthetic cannabinoids places people who use these substances and others at risk of injury (Capron, 2016; Kaneko, 2017; Karinen et al., 2015; Musshoff et al., 2014). The extent of impairment in cases involving motor vehicle accidents was considered severe for a range of different synthetic cannabinoids, and examples from reports include: loss of consciousness, lane travel, causing collisions, erratic driving, speeding, poor coordination and focus, confusion, aggressiveness, slow response to questioning, incoherent speech, excited states such as agitation, shouting, confusion, and continuous stereotyped behaviours (Capron, 2016; Kaneko, 2017). Similarly, the operation of machinery while under the influence of synthetic cannabinoids may place the people who use these substances and others at risk of injury.

6.3 Chronic health effects

Specific information about 4F-MDMB-BICA could not be identified. Similar to other synthetic cannabinoids, chronic use has been associated with greater risks for developing mental health disorder than cannabis (Cohen and Weinstein, 2018; Skryabin and Vinnikova, 2018), which may include dependence. Acute and chronic use of synthetic cannabinoids has also been associated with detrimental cardiovascular health (Ozturk et al., 2019; Pacher et al., 2018).

7. Social risks

Whilst there is limited information for 4F-MDMB-BICA, the social risks might share some similarities with cannabis and other synthetic cannabinoids. Of particular note is that synthetic cannabinoids are increasingly used by vulnerable groups, such as prisoners and

people experiencing homelessness. Reports suggest that this has caused new health and social problems as well as exacerbated existing ones for these groups. For example, in prisons, alongside the adverse health effects, such as acute poisonings, the market in synthetic cannabinoids has been linked to an increase in bullying and debt, as well as aggression and violence. In some cases this has caused a serious threat to the overall safety and security of the prison environment (Blackman and Bradley, 2017; HMIP, 2015; Ralphs et al., 2017; User Voice, 2016). As such, it is a concern that 4F-MDMB-BICA has been seized in prisons and other custodial settings in at least 5 Member States during 2020.

7.1 Individual social risks

While there is no specific information on whether the use of 4F-MDMB-BICA causes individual social risks, any such risks may have some similarities with those associated with cannabis and other synthetic cannabinoids. These may impact on education or career, family or other personal and social relationships and may result in marginalisation.

7.2 Possible effects on direct social environment

While there is no specific information on the possible effects of 4F-MDMB-BICA on the direct social environment, the behavioural effects of synthetic cannabinoids include reports of aggressive and violent behaviour. This may place users and others at risk of injury.

7.3 Possible effects on society as a whole

While there is no specific information on the possible effects of 4F-MDMB-BICA on society as a whole, the behavioural effects of synthetic cannabinoids include reports of aggressive and violent behaviour. In particular, concern was expressed in this regard to use in certain environments such as prisons and psychiatric institutions.

In prisons, alongside the adverse health effects, such as acute poisonings, the market in synthetic cannabinoids has been linked to an increase in bullying and debt, as well as aggression and violence. In some cases this has caused a serious threat to the overall safety and security of the prison environment.

Due to lack of data, it is not possible at this time to estimate the social risk associated with the trafficking and distribution of 4F-MDMB-BICA.

7.4 Economic costs

There is no information on the health and social costs related to 4F-MDMB-BICA. As 4F-MDMB-BICA is a synthetic cannabinoid, any such costs may have some similarities with those associated with the use of cannabis and other synthetic cannabinoids.

7.5 Possible effects related to the cultural context, for example marginalisation

There is no information on the possible effects of 4F-MDMB-BICA related to the cultural context. As 4F-MDMB-BICA is a synthetic cannabinoid, any such effects may have some similarities with those associated with the use of cannabis and other synthetic cannabinoids.

7.6 Possible appeal to specific population groups within the general population

There is limited information on the possible appeal to specific population groups. As 4F-MDMB-BICA is a synthetic cannabinoid, it could be expected that suppliers as well as users who are looking for 'legal' substitutes for cannabis and replacements for controlled synthetic cannabinoids, may be interested in 4F-MDMB-BICA. This may include individuals subject to drug testing (such as drivers, prisoners, those in drug treatment, and those subject to workplace drug testing), as commonly used drug tests may be unable to detect the compounds.

Reports suggest that in some areas, high-risk drug users and other vulnerable groups, such as prisoners and people experiencing homelessness, may specifically seek out synthetic cannabinoids as they are readily available and have gained a reputation for causing profound intoxication while being comparatively cheaper to other drugs. In addition, synthetic cannabinoids, particularly when impregnated on to paper, can be easy to smuggle into prison and other custodial settings.

Although limited, there is some information to suggest a recent increase in vaping of synthetic cannabinoids using electronic cigarettes by young people, including teenagers, in some Member States; in some cases, the users believed that they were using cannabidiol (CBD) or THC.

Similar to other new psychoactive substances, it also appears that there is interest in 4F-MDMB-BICA by people who experiment with a range of psychoactive substances (so-called 'psychonauts').

7.7 Involvement of criminal groups in the manufacture, distribution and distribution methods, and trafficking

There is no information whether or not criminal groups are involved in the manufacture, trafficking, and distribution of 4F-MDMB-BICA within Europe (EMCDDA, 2020b).

The effect of the on-going COVID-19 pandemic (ECDD, 2020; EMCDDA, 2020e; WHO, 2020b) on the manufacture, trafficking, distribution, and use of 4F-MDMB-BICA is currently unknown. Seizures of bulk powders by European national customs agencies during the

pandemic suggests that it continues to be imported into and distributed within Europe. It is possible, that in case of a reduced availability of cannabis and other synthetic cannabinoids in Europe, criminal groups, as well as drug users, may use a range of replacement substances, including 4F-MDMB-BICA.

8. Other relevant information

8.1 Information on restrictive measures

8.1.1 *International restrictive measures*

At international level, 4F-MDMB-BICA is not controlled under the United Nations Single Convention on Narcotic Drugs, 1961, as amended by the 1972 Protocol, or the Convention on Psychotropic Substances of 1971 ('United Nations system') (UNODC, 2020a; UNODC, 2020b). 4F-MDMB-BICA has not been subject to assessment nor is it currently under assessment by the United Nations system (EMCDDA, 2020b).

8.1.2 *National restrictive measures*

Fifteen Member States (Bulgaria, Czechia, Denmark, Estonia, Finland, Greece, Ireland, Malta, the Netherlands, Portugal, Romania, Slovakia, Slovenia, Spain, and Sweden) reported that 4F-MDMB-BICA is not subject to restrictive measures at national level (EMCDDA, 2020b).

4F-MDMB-BICA is subject to restrictive measures in thirteen Member States: in Croatia, Cyprus, France, Italy, Latvia, Luxembourg, Poland, and the United Kingdom the substance is controlled under drug control legislation; in Lithuania it is controlled under medicines legislation; in Austria, Belgium, Germany, and Hungary it is controlled by new psychoactive substance legislation. In addition, 4F-MDMB-BICA is controlled under medicines legislation in Norway and under drug control legislation in Turkey (EMCDDA, 2020b).

It is unknown if 4F-MDMB-BICA is controlled in China, where at least some of the substance on the European market has been sourced from.

9. References

- ADEBAR (2020), *Analytical Report. 4F-MDMB-BICA. Methyl 2-([1-(4-Fluorobutyl)-1H-indol-3-yl]carbonyl)-amino)-3,3- dimethylbutanoate*. ADEBAR plus project. Sample ID: 20/ADB-056 and 20/ADB-057.
- Antonides, L. H., Cannaert, A., Norman, C., NicDaeid, N., Sutcliffe, O. B., Stove, C. and McKenzie, C. (2020), 'Shape matters: the application of activity-based *in vitro* bioassays and chiral profiling to the pharmacological evaluation of synthetic cannabinoid receptor agonists in drug-infused papers seized in prisons', *Drug Testing and Analysis*, <https://doi.org/doi.org/10.1002/dta.2965>
- Auwärter, V., Dresen, S., Weinmann, W., Müller, M., Pütz, M., and Ferreirós, N. (2009), 'Spice' and other herbal blends: harmless incense or cannabinoid designer drugs? ', *Journal of Mass Spectrometry*, 44(5), pp. 832–837. <https://doi.org/10.1002/jms.1558>
- Banister, S. D., Longworth, M., Kevin, R., Sachdev, S., Santiago, M., Stuart, J., Mack, J. B. C., Glass, M., McGregor, I. S., Connor, M. and Kassiou, M. (2016), 'Pharmacology of valinate and tert-leucinate synthetic cannabinoids 5F-AMBICA, 5F-AMB, 5F-ADB, AMB-FUBINACA, MDMB-FUBINACA, MDMB-CHMICA, and their analogues', *ACS Chemical Neuroscience*, 7(9), pp. 1241-1254. <https://doi.org/10.1021/acscchemneuro.6b00137>
- Banister, S. D. and Connor, M. (2018), 'The chemistry and pharmacology of synthetic cannabinoid receptor agonist new psychoactive substances: evolution', *Handbook of Experimental Pharmacology*, 252, pp. 191-226. https://doi.org/10.1007/164_2018_144
- Banister, S. D., Adams, A., Kevin, R. C., Macdonald, C., Glass, M., Boyd, R., Connor, M., McGregor, I. S., Havel, C. M., Bright, S. J., Vilamala, M. V., Lladanosa, C. G., Barratt, M. J. and Gerona, R. R. (2019), 'Synthesis and pharmacology of new psychoactive substance 5F-CUMYL-P7AICA, a scaffold-hopping analog of synthetic cannabinoid receptor agonists 5F-CUMYL-PICA and 5F-CUMYL-PINACA', *Drug Testing and Analysis*, 11(2), pp. 279-291. <https://doi.org/10.1002/dta.2491>
- Blackman, S. and Bradley, R. (2017), 'From niche to stigma—Headshops to prison: Exploring the rise and fall of synthetic cannabinoid use among young adults', *International Journal on Drug Policy*, 40, pp. 70-77. <https://doi.org/10.1016/j.drugpo.2016.10.015>
- Buchler, I. P., Hayes, M. J., Hegde, S. G., Hockerman, S. L., Jones, D. E., Kortum, S. W., Rico, J. G., Tenbrink, R. E. and Wu, K. K. (2009), *Indazole derivatives*, WO2009106980A2. Pfizer Inc., New York, USA.
- Cannaert, A., Sparkes, E., Pike, E., Luo, J. L., Fang, A., Kevin, R., Ellson, R., Gerona, R., D., B. S. and Stove, C. P. (2020), 'Synthesis and *in vitro* cannabinoid receptor 1 (CB₁) activity of recently detected synthetic cannabinoids 4F-MDMB-BICA, 5F-MPP-PICA, MMB-4en-PICA, CUMYL-CBMICA, ADB- BINACA, APP-BINACA, 4F-MDMB-BINACA, MDMB-4en-PINACA, A-CHMINACA, 5F-AB-P7AICA, 5F-MDMB-P7AICA, and 5F-AP7AICA', submitted manuscript.

Capron, B. (2016), '5F-ADB drivers in the State of Washington', *ToxTalk*, 40(2), pp. 23-26. Available at: http://www.soft-tox.org/files/toxtalk/SOFT_ToxTalk_v40-22_20.pdf [last accessed 13 Oct 2020].

Cayman Chemical Company (2020a), *Product information. 4-fluoro MDMB-BUTICA*. Cayman Chemical Company, Ann Arbor, MI, USA. Available at: <https://www.caymanchem.com/pdfs/31075.pdf> [last accessed 18 Nov 2020].

Cayman Chemical Company (2020b), *Safety data sheet. 4-fluoro MDMB-BUTICA*, Cayman Chemical Company, Ann Arbor, MI, USA. Available at: <https://www.caymanchem.com/msdss/31075m.pdf> [last accessed 18 Nov 2020].

Cayman Chemical Company (2020c), *Cayman spectral library. GC-MS data. 4-fluoro MDMB-BUTICA*, Cayman Chemical Company, Ann Arbor, MI, USA. Available at: <https://www.caymanchem.com/gcms/31075-0589507-GCMS.pdf> [last accessed 18 Nov 2020].

United Nations Commission on Narcotic Drugs (CND) (2020), *Report on the sixty-third session* (13 December 2019 and 2-6 March 2020). Advance Version. E/2020/28E/CN.7/2020/15. Economic and Social Council Official Records, 2020 Supplement No. 8. Available at: https://www.unodc.org/documents/commissions/CND/CND_Sessions/CND_63/E2020_28_e_V2001956_Advance_Version.pdf [last accessed 17 Oct 2020].

Cohen, K. and Weinstein, A. M. (2018), 'Synthetic and non-synthetic cannabinoid drugs and their adverse effects - a review from public health perspective', *Frontiers in Public Health*, 6, 162. <https://doi.org/10.3389/fpubh.2018.00162>

Cooper, Z. D. (2016), 'Adverse effects of synthetic cannabinoids: management of acute toxicity and withdrawal', *Current Psychiatry Reports*, 18(5), 52. <https://doi.org/10.1007/s11920-016-0694-1>

Diao, X. and Huestis, M. A. (2019), 'New synthetic cannabinoids metabolism and strategies to best identify optimal marker metabolites', *Frontiers in Chemistry*, 7, 109. <https://doi.org/10.3389/fchem.2019.00109>.

ECDC (European Centre for Disease Control and Prevention) (2020), *COVID-19*. <https://www.ecdc.europa.eu/en/covid-19-pandemic>

EMCDDA (European Monitoring Centre for Drugs and Drug Addiction) (2009), *Understanding the 'Spice' phenomenon*, Publications Office of the European Union, Luxembourg. <http://www.emcdda.europa.eu/system/files/publications/537/Spice-Thematic-paper-final-version.pdf>

EMCDDA (2017), *Report on the risk assessment of methyl 2-[[1-(cyclohexylmethyl)-1H-indole-3-carbonyl]amino]-3,3-dimethylbutanoate (MDMB-CHMICA) in the framework of the Council Decision on new psychoactive substances*, EMCDDA, Lisbon. Available at: https://www.emcdda.europa.eu/system/files/publications/4093/TDAK16002ENN_PDFWEB.

pdf_en [last accessed 22 Nov 2020].

EMCDDA (2018), *Report on the risk assessment of methyl 2-([1-(5-fluoropentyl)-1H-indazole-3-carbonyl]amino)-3,3-dimethylbutanoate (5F-MDMB-PINACA) in the framework of the Council Decision on new psychoactive substances*, EMCDDA, Lisbon. Available at: [https://www.emcdda.europa.eu/system/files/publications/9122/Risk assessment 5F-MDMB-PINACA.pdf](https://www.emcdda.europa.eu/system/files/publications/9122/Risk%20assessment%205F-MDMB-PINACA.pdf) [last accessed 18 Nov 2020].

EMCDDA (2019), *Guidance note 1. Terminology and definitions. EMCDDA operating guidelines for the European Union Early Warning System on new psychoactive substances*. Available at: [https://www.emcdda.europa.eu/system/files/publications/12213/downloads/Guidance Note 1- Terminology and definitions.pdf](https://www.emcdda.europa.eu/system/files/publications/12213/downloads/Guidance%20Note%201-Terminology%20and%20definitions.pdf) [last accessed 12 Oct 2020].

EMCDDA (2020a), *EU Early Warning System Alert. Deaths associated with 4F-MDMB-BICA - Hungary*, May-August 2020. RCS ID: EU-EWS-RCS-AL-2020-0002.

EMCDDA (2020b), *EMCDDA initial report on the new psychoactive substance methyl 2-([1-(4-fluorobutyl)-1H-indol-3-yl]carbonyl]amino)-3,3-dimethylbutanoate (4F-MDMB-BICA). In accordance with Article 5b of Regulation (EC) No 1920/2006 (as amended)*, EMCDDA, Lisbon, Portugal.

EMCDDA (2020c), *EMCDDA initial report on the new psychoactive substance methyl 3,3-dimethyl-2-[1-(pent-4-en-1-yl)-1H-indazole-3-carboxamido]butanoate (MDMB-4en-PINACA). In accordance with Article 5b of Regulation (EC) No 1920/2006 (as amended)*, EMCDDA, Lisbon, Portugal. Available at: https://www.emcdda.europa.eu/publications/initial-reports/4f-mdmb-bica_en [last accessed 18 Nov 2020].

EMCDDA (2020d), *EU Early Warning System Formal Notification. Formal notification of methyl 2-([1-(4-fluorobutyl)-1H-indol-3-yl]carbonyl]amino)-3,3-dimethylbutanoate (4F-MDMB-BICA) by Belgium as a new psychoactive substance under the terms of Regulation (EU) 2017/2101*. RCS ID: EU-EWS-RCS-FN-2020-0019.

EMCDDA (2020e), *EMCDDA update on the implications of COVID-19 for people who use drugs (PWUD) and drug service providers*, EMCDDA, Lisbon. <https://www.emcdda.europa.eu/system/files/publications/12879/emcdda-covid-update-1-25.03.2020v2.pdf>

Ernst, L., Brandhorst, K., Papke, U., Altrogge, A., Zedel, S., Langer, N., Beuerle, T. (2017), 'Identification and quantification of synthetic cannabinoids in 'spice-like' herbal mixtures: Update of the German situation in early 2017', *Forensic Sci Int* 277:51–58. <https://doi.org/10.1016/j.forsciint.2017.05.019>

Erowid (2020), *DrugsData.org. Erowid's anonymous drug analysis program, formerly called EcstasyData*. Available at: https://drugsdata.org/results.php?search_field=all&s=4F-MDMB-BICA [last accessed 25 Oct 2020].

Ford, B. M., Tai, S., Fantegrossi, W. E. and Prather, P. L. (2017), 'Synthetic pot: not your grandfather's marijuana', *Trends in Pharmacological Sciences*, 38(3), pp. 257-276. <https://doi.org/10.1016/j.tips.2016.12.003>

Frinculescu, A., Lyall, C. L., Ramsey, J. and Miserez, B. (2017), 'Variation in commercial smoking mixtures containing third-generation synthetic cannabinoids', *Drug Testing and Analysis*, 9(2), pp. 327-333. <https://doi.org/10.1002/dta.1975>

Gaoni, Y. and Mechoulam, R. (1964), 'Isolation, structure, and partial synthesis of an active constituent of hashish', *Journal of the American Chemical Society*, 86(8), pp. 1646–1647. <https://doi.org/10.1021/ja01062a046>

Giorgetti, A., Busardò, F. P., Tittarelli, R., Auwärter, V. and Giorgetti, R. (2020), 'Post-mortem toxicology: a systematic review of death cases involving synthetic cannabinoid receptor agonists', *Frontiers in Psychiatry*, 11, 464. <https://doi.org/10.3389/fpsy.2020.00464>

Haschimi, B., Mogler, L., Halter, S., Giorgetti, A., Schwarze, B., Westphal, F., Fischmann, S. and Auwärter, V. (2019), 'Detection of the recently emerged synthetic cannabinoid 4F-MDMB-BINACA in "legal high" products and human urine specimens', *Drug Testing and Analysis*, 11(9), pp. 1377-1386. <https://doi.org/10.1002/dta.2666>

Hermanns-Clausen, M., Kneisel, S., Szabo, B. and Auwärter, V. (2013), 'Acute toxicity due to the confirmed consumption of synthetic cannabinoids: clinical and laboratory findings', *Addiction*, 108(3), pp. 534-544. <https://doi.org/10.1111/j.1360-0443.2012.04078.x>

Hungarian Institute for Forensic Sciences (HIFS) (2020), *Analytical data for 4F-MDMB-BICA. RPT: HIFS-020*, Hungarian Institute for Forensic Sciences, Budapest, Hungary. Available at: https://www.policija.si/apps/nfl_response_web/0_Analytical_Reports_final/4F-MDMB-BICA-ID-HIFS-020.pdf [last accessed 18 Nov 2020].

Her Majesty's Inspectorate of Prisons (HMIP) (2015), *Changing patterns of substance misuse in adult prisons and service responses*, Her Majesty's Inspectorate of Prisons, London. Available at: <https://www.justiceinspectores.gov.uk/hmiprison/wp-content/uploads/sites/4/2015/12/Substance-misuse-web-2015.pdf> [last accessed 26 Oct 2020].

Huestis, M. A., Gorelick, D. A., Heishman, S. J., Preston, K. L., Nelson, R. A., Moolchan, E. T. and Frank, R. A. (2001), 'Blockade of effects of smoked marijuana by the CB₁-selective cannabinoid receptor antagonist SR141716', *Archives of General Psychiatry*, 58(4), pp. 322–328. <https://doi.org/10.1001/archpsyc.58.4.322>

International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for human use (ICH) (2000), *ICH harmonized tripartite guideline. S7A Safety Pharmacology Studies for Human Pharmaceuticals*. Available at: https://database.ich.org/sites/default/files/S7A_Guideline.pdf [last accessed 13 Oct 2020].

International Narcotics Control Board (INCB) (2019), *List of Psychotropic Substances under International Control (Green List)*. In accordance with the Convention on Psychotropic Substances of 1971. 30th edition, 2019. Available at: https://www.incb.org/documents/Psychotropics/forms/greenlist/Green_list_ENG_08673.pdf [last accessed 12 Oct 2020].

Jack, A., (2009), 'The Story of Spice', *Financial Times*.
<https://www.ft.com/content/1721e2da-f8a0-11dd-aae8-000077b07658?mhq5j=e5> [last accessed 18 Nov 2020]

Kaneko, S. (2017), 'Motor vehicle collisions caused by the 'super-strength' synthetic cannabinoids, MAM-2201, 5F-PB-22, 5F-AB-PINACA, 5F-AMB and 5F-ADB in Japan experienced from 2012 to 2014', *Forensic Toxicology*, 35(2), pp. 244-251.
<https://doi.org/10.1007/s11419-017-0369-6>

Karinen, R., Tuv, S. S., Øiestad, E. L. and Vindenes, V. (2015), 'Concentrations of APINACA, 5F-APINACA, UR-144 and its degradant product in blood samples from six impaired drivers compared to previous reported concentrations of other synthetic cannabinoids', *Forensic Science International*, 246, pp. 98-103.
<https://doi.org/10.1016/j.forsciint.2014.11.012>

Kleis, J., Germerott, T., Halter, S., Héroux, V., Roehrich, J., Schwarz, C. S. and Hess, C. (2020), 'The synthetic cannabinoid 5F-MDMB-PICA: a case series', *Forensic Science International*, 314, 110410. <https://doi.org/10.1016/j.forsciint.2020.110410>

Krotulski, A. J., Mohr, A. L. A., Kacinko, S. L., Fogarty, M. F., Shuda, S. A., Diamond, F. X., Kinney, W. A., Menendez, M. J. and Logan, B. K. (2019), '4F-MDMB-BINACA: a new synthetic cannabinoid widely implicated in forensic casework', *Journal of Forensic Sciences*, 64(5), pp. 1451-1461. <https://doi.org/10.1111/1556-4029.14101>

Krotulski, A. J., Shuda, S. S., Fogart, M. F., Decker, S. E. and Logan, B. K. (2020), *4F-MDMB-BICA. NPS Discovery*, The Center for Forensic Science Research and Education, Willow Grove, PA, USA. Available at: https://www.npsdiscovery.org/wp-content/uploads/2020/06/4F-MDMB-BICA_070120_NMSLabs_Report.pdf [last accessed 18 Nov 2020].

Langer, N., Lindigkeit, R., Schiebel, H.M., Ernst, L., Beuerle, T. (2014), 'Identification and quantification of synthetic cannabinoids in 'spice-like' herbal mixtures: a snapshot of the German situation in the autumn of 2012', *Drug Testing and Analysis* 6:59-71.
<https://doi.org/10.1002/dta.1499>

Langer, N., Lindigkeit, R., Schiebel, H.M., Papke, U., Ernst, L., Beuerle, T. (2016), 'Identification and quantification of synthetic cannabinoids in "spice-like" herbal mixtures: update of the German situation for the spring of 2016', *Forensic Sci Int* 269:31-41.
<https://doi.org/10.1016/j.forsciint.2016.10.023>

Lowe, D. M., Corbett, P. T., Murray-Rust, P. and Glen, R. C. (2011), 'Chemical name to structure: OPSIN, an open source solution', *Journal of Chemical Information and Modeling*, 51(3), pp. 739-753. <https://doi.org/10.1021/ci100384d>

Macfarlane, V. and Christie, G. (2015), 'Synthetic cannabinoid withdrawal: a new demand on detoxification services', *Drug and Alcohol Review*, 34(2), pp. 147-153. <https://doi.org/10.1111/dar.12225>

McKenzie, C. (2020), *Summary Report on the Synthetic Cannabinoids MDMB-4en-PINACA and 4F-MDMB-BICA*, Report to UK national focal point 18th September 2020, Leverhulme Research Centre for Forensic Science (LRCFS), University of Dundee, Scotland.

Mogler, L., Franz, F., Rentsch, D., Angerer, V., Weinfurter, G., Longworth, M., Banister, S. D., Kassiou, M., Moosmann, B. and Auwärter, V. (2018), 'Detection of the recently emerged synthetic cannabinoid 5F-MDMB-PICA in 'legal high' products and human urine samples', *Drug Testing and Analysis*, 10(1), pp. 196-205. <https://doi.org/10.1002/dta.2201>

Moosmann, B., Angerer, V. and Auwärter, V. (2015), 'Inhomogeneities in herbal mixtures: a serious risk for consumers', *Forensic Toxicology*, 33(1), pp. 54-60. <https://doi.org/10.1007/s11419-014-0247-4>

Musshoff, F., Madea, B., Kernbach-Wighton, G., Bicker, W., Kneisel, S., Hutter, M. and Auwärter, V. (2014), 'Driving under the influence of synthetic cannabinoids ("Spice"): a case series', *International Journal of Legal Medicine*, 128(1), pp. 59-64. <https://doi.org/10.1007/s00414-013-0864-1>

NFL Ljubljana (2020), *Analytical Report. 4F-MDMB-BICA (C₂₀H₂₇FN₂O₃)*, European Project Response 2. National Forensic Laboratory (NFL), Ljubljana, Slovenia. Available at: https://www.policija.si/apps/nfl_response_web/0_Analytical_Reports_final/4F-MDMB-BICA-ID-2189-20_report.pdf [last accessed 17 Oct 2020].

Noble, C., Cannaert, A., Linnet, K. and Stove, C. P. (2019), 'Application of an activity-based receptor bioassay to investigate the *in vitro* activity of selected indole- and indazole-3-carboxamide-based synthetic cannabinoids at CB₁ and CB₂ receptors', *Drug Testing and Analysis*, 11(3), pp. 501-511. <https://doi.org/10.1002/dta.2517>

Norman, C., McKirdy, B., Walker, G., Dugard, P., Nic Daéid, N. and McKenzie, C. (2020), 'Large-scale evaluation of ion mobility spectrometry for the rapid detection of synthetic cannabinoid receptor agonists in infused papers in prisons', *Drug Testing and Analysis*, <https://doi.org/doi.org/10.1002/dta.2945>

Ong, R. S., Kappatos, D. C., Russell, S. G. G., Poulsen, H. A., Banister, S. D., Gerona, R. R., Glass, M., Johnson, C. S. and McCarthy, M.-J. (2020), 'Simultaneous analysis of 29 synthetic cannabinoids and metabolites, amphetamines, and cannabinoids in human whole blood by liquid chromatography–tandem mass spectrometry – a New Zealand perspective of use in 2018', *Drug Testing and Analysis*, 12(2), pp. 195-214. <https://doi.org/10.1002/dta.2697>

Ozturk, H. M., Yetkin, E. and Ozturk, S. (2019), 'Synthetic cannabinoids and cardiac arrhythmia risk: review of the literature', *Cardiovascular Toxicology*, 19(3), pp. 191-197. <https://doi.org/10.1007/s12012-019-09522-z>

Pacher, P., Steffens, S., Haskó, G., Schindler, T. H. and Kunos, G. (2018), 'Cardiovascular effects of marijuana and synthetic cannabinoids: the good, the bad, and the ugly', *Nature Reviews. Cardiology*, 15(3), pp. 151-166. <https://doi.org/10.1038/nrcardio.2017.130>

Persson, M., Kronstrand, R. and Gréen, H. (2020), *Rapport angående aktivering av CB₁ receptor För 4-fluoro MDMB-BUTICA*. Rapport nr: 040; 2020-09-25. National Board of Forensic Medicine, Sweden.

Pertwee RG (ed). (2005a), *Cannabinoids. Handbook of Experimental Pharmacology*, Vol. 231, Berlin: Springer, Cham. <https://link.springer.com/book/10.1007/b137831>

Pertwee, R. G. (2005b), 'The therapeutic potential of drugs that target cannabinoid receptors or modulate the tissue levels or actions of endocannabinoids', *AAPS Journal*, 7(3), pp. E625–E654. <https://doi.org/10.1208/aapsj070364>

Pertwee, R. G., (Ed). (2014), *Handbook of cannabis*, Oxford University Press, Oxford.

Pertwee, R. G., (Ed). (2015), *Endocannabinoids*, Handbook.

Ralphs, R., Williams, L., Askew, R. and Norton, A. (2017), 'Adding Spice to the porridge: the development of a synthetic cannabinoid market in an English prison', *International Journal on Drug Policy*, 40, pp. 57-69. <https://doi.org/10.1016/j.drugpo.2016.10.003>

Rave it Safe (2020), Contact. Stiftung für Suchthilfe. Rave it Safe. Drug Checking. Aktuelle Warnungen. Available at: <http://drugcheck.raveitsafe.ch/> [last accessed 06 Oct 2020].

Reddit (2020), *4F-MDMB-BICA*. Search results. Available at: <https://www.reddit.com/search/?q=4F-MDMB-BICA> [last accessed 17 Oct 2020].

Reggio, P. H. (Ed). (2009), *The cannabinoids receptors*, Humana Press, New York, <https://doi.org/10.1007/978-1-59745-503-9>

Saferparty.ch (2020), Stadt Zürich, Soziale Einrichtungen und Betriebe, Saferparty. Available at: <https://www.saferparty.ch/231.html> [last accessed 25 Oct 2020].

Schäper, J. (2016), 'Wirkstoffgehalte und inhomogene Verteilung des Wirkstoffs MDMB-CHMICA in Kräutermischungen', *Toxichem Krimtech* 83:112–114.

Skryabin, V. Y. and Vinnikova, M. A. (2018), 'Clinical characteristics of synthetic cannabinoid-induced psychotic disorders: a single-center analysis of hospitalized patients', *Journal of Addictive Diseases*, 37(3-4), pp. 135-141. <https://doi.org/10.1080/10550887.2019.1627635>

Tait, R. J., Caldicott, D., Mountain, D., Hill, S. L. and Lenton, S. (2016), 'A systematic review of adverse events arising from the use of synthetic cannabinoids and their associated treatment', *Clinical Toxicology*, 54(1), pp. 1-13.
<https://doi.org/10.3109/15563650.2015.1110590>

Tihanyi, M., Mátyás, S., Vári, V. and Krasnova, K. A. (2020), 'Socio-demographic characteristics of drug users and drug addicts in Hungary', *Виктимология*, 25(3), pp. 53-60.

UNODC (United Nations Office on Drugs and Crime) (2020a), *Schedules of the Single Convention on Narcotic Drugs of 1961 as amended by the 1972 Protocol, as at 07 May 2020*. <https://www.unodc.org/unodc/en/commissions/CND/conventions.html>

UNODC (United Nations Office on Drugs and Crime) (2020b), *Schedules of the Convention on Psychotropic Substances of 1971, as at 03 November 2020*.
<https://www.unodc.org/unodc/en/commissions/CND/conventions.html>

User Voice (2016), *Spice: the bird killer - what prisoners think about the use of spice and other legal highs in prison*. Available at: <https://www.uservice.org/wp-content/uploads/2020/07/User-Voice-Spice-The-Bird-Killer-Report-compressed.pdf> [last accessed 26 Oct 2020].

Van Hout, M. C. and Hearne, E. (2017), 'User experiences of development of dependence on the synthetic cannabinoids, 5f-AKB48 and 5F-PB-22, and subsequent withdrawal syndromes', *International Journal of Mental Health and Addiction*, 15(3), pp. 565-579.
<https://doi.org/10.1007/s11469-016-9650-x>

Wagmann, L., Frankenfeld, F., Park, Y. M., Herrmann, J., Fischmann, S., Westphal, F., Müller, R., Flockerzi, V. and Meyer, M. R. (2020), 'How to study the metabolism of new psychoactive substances for the purpose of toxicological screenings - a follow-up study comparing pooled human liver S9, HepaRG Cells, and zebrafish Larvae', *Frontiers in Chemistry*, 8, 539. <https://doi.org/10.3389/fchem.2020.00539>

World Health Organization (WHO) (2017), *Critical Review Report: 5F-ADB*. Expert Committee on Drug Dependence, Thirty-ninth meeting, 6-10 November 2017, Geneva, Switzerland. Available at: https://www.who.int/medicines/access/controlled-substances/Critical_Review_5F-ADB.pdf [last accessed 18 Nov 2020].

WHO (2019a), *Critical Review Report: 5F-MDMB-PICA*, Expert Committee on Drug Dependence. Forty-second Meeting, Geneva, Switzerland, 21-25 October 2019. Available at: https://www.who.int/medicines/access/controlled-substances/Final_5F-MDMB-PICA.PDF?ua=1 [last accessed 18 Nov 2020].

WHO (2019b), *Critical Review Report: 4F-MDMB-BINACA*, Expert Committee on Drug Dependence. Forty-second Meeting, Geneva, Switzerland, 21-25 October 2019. Available at: https://www.who.int/medicines/access/controlled-substances/Final_4F-MDMB-BINACA.PDF?ua=1 [last accessed 18 Nov 2020].

WHO (2020a), *Critical Review Report: MDMB-4en-PINACA*, Expert Committee on Drug Dependence. Forty-third Meeting. Geneva, Switzerland, 12-20 October 2020. Available at: https://www.who.int/docs/default-source/controlled-substances/43rd-ecdd/mdmb-4en-pinaca-review-2020.pdf?sfvrsn=5cd6e97e_4 [last accessed 18 Nov 2020].

WHO (2020b), *Coronavirus disease (COVID-19) pandemic*.
<https://www.who.int/emergencies/diseases/novel-coronavirus-2019>

Wiley, J. L., Lefever, T. W., Glass, M. and Thomas, B. F. (2019), 'Do you feel it now? Route of administration and Δ^9 -tetrahydrocannabinol-like discriminative stimulus effects of synthetic cannabinoids in mice', *Neurotoxicology*, 73, 161-167.
<https://doi.org/10.1016/j.neuro.2019.04.002>

Wiley, J. L., Marusich, J. A. and Thomas, B. F. (2017), 'Combination chemistry: structure-activity relationships of novel psychoactive cannabinoids', *Current Topics in Behavioral Neurosciences*, 32, 231-248. https://doi.org/10.1007/7854_2016_17

Wiley, J. L., Owens, R. A. and Lichtman, A. H. (2018), 'Discriminative stimulus properties of phytocannabinoids, endocannabinoids, and synthetic cannabinoids', *Current Topics in Behavioral Neurosciences*, 39, 153-173. https://doi.org/10.1007/7854_2016_24

Yalçın, M., Tunalı, N., Yıldız, H., Oğuz, A. and Gültekin, B. K. (2018), 'Sociodemographic and clinical characteristics of synthetic cannabinoid users in a large psychiatric emergency department in Turkey', *Journal of Addictive Diseases*, 37(3-4), pp. 259-267.
<https://doi.org/10.1080/10550887.2019.1671146>

Yeter, O. (2017), 'Identification of the synthetic cannabinoid 1-(4-cyanobutyl)-N-(2-phenylpropan-2-yl)-1H-indazole-3-carboxamide (CUMYL-4CN-BINACA) in plant material and quantification in post-mortem blood samples', *Journal of Analytical Toxicology*, 41(9), pp. 720-728. <https://doi.org/10.1093/jat/bkx061>

Zaurova, M., Hoffman, R. S., Vlahov, D. and Manini, A. F. (2016), 'Clinical effects of synthetic cannabinoid receptor agonists compared with marijuana in emergency department patients with acute drug overdose', *Journal of Medical Toxicology*, 12(4), pp. 335-340. <https://doi.org/10.1007/s13181-016-0558-4>

Zimmermann, U. S., Winkelmann, P. R., Pilhatsch, M., Nees, J. A., Spanagel, R. and Schulz, K. (2009), 'Withdrawal phenomena and dependence syndrome after the consumption of "Spice Gold"', *Deutsches Ärzteblatt International*, 106(27), pp. 464-467.
<https://doi.org/10.3238/arztebl.2009.0464>

ANNEX 2

Participants of the risk assessment meeting, 7 December 2020

Extended Scientific Committee*

Professor Dr Henri BERGERON

Centre National de la Recherche Scientifique (CNRS), Institut d'Études Politiques de Paris (IEP Paris), Paris
Vice-Chair of the Scientific Committee

Dr Anne Line BRETTEVILLE-JENSEN

Norwegian Institute for Alcohol and Drug Research, Oslo

Professor Dr Catherine COMISKEY

Director, Centre for Practice and Healthcare Innovation, Trinity College Dublin, Dublin
Chair of the Scientific Committee

Professor Dr Fabrizio FAGGIANO

Department of Translational Medicine of Università del Piemonte Orientale and
Epidemiologic Observatory of the Local Health Unit of Vercelli, Novara

Professor Dr Gabriele FISCHER

Medical University Vienna, Center of Public Health, Department of Psychiatry &
Psychotherapy, Vienna

Professor Dr Matthew HICKMAN

School of Social and Community Medicine, University of Bristol, Bristol

Dr Marie JAUFFRET-ROUSTIDE

French Institute of Health and Medical Research, Inserm, Center of Medicine, Sciences,
Health, Mental Health and Health Policy CERMES 3, Paris

Professor Dr Krzysztof KRAJEWSKI

Department of Criminology, Jagiellonian University, Krakow

Dr Marieke LIEM

Violence Research Initiative FGGA, Leiden University, The Hague

Dr Kim MOELLER

Faculty of Health and Society, Department of Criminology, Malmö University, Malmö

Professor Dr Ilkka OJANPERÄ

Department of Forensic Medicine, University of Helsinki and Forensic Toxicology Unit,
Helsinki

* Following the procedure laid down in Article 5c(4) of Regulation (EC) No 1920/2006 (as amended), the Scientific Committee of the EMCDDA has been extended with five additional experts.

Dr Fernando RODRÍGUEZ de FONSECA

Fundación IMABIS, Hospital Universitario Carlos Haya de Málaga, Málaga

Professor Dr Marta TORRENS MÈLICH

Universitat Autònoma de Barcelona

Hospital del Mar, Medical Research Institute and NeuroPsychiatry and Addictions Institute, Barcelona

Dr Leon Van AERTS

Section Pharmacology, Toxicology and Biotechnology, College ter Beoordeling van Geneesmiddelen, Medicines Evaluation Board, Utrecht

Dr Simon BRANDT

School of Pharmacy & Biomolecular Sciences, Liverpool John Moores University, Liverpool

Dr Pirkko KRIIKKU

National Institute for Health and Welfare, Helsinki

Dr István UJVÁRY

Budapest University of Technology and Economics, Budapest

Observers

Edith HOFER

Organised Crime and Drugs Policy Unit, Directorate-General for Migration and Home Affairs, European Commission

Dr Claude GUILLOU

Health, Consumers and Reference Materials, Directorate-General Joint Research Centre, European Commission

Iwona PERKOWSKA

Human Division, Pharmacovigilance Office, Europol

Izabela SKIBICKA-STEPHEN

Office of Therapies for neurological and psychiatric disorders, European Medicines Agency

Dr Roumen SEDEFOV

Head of Unit, Risks to public safety and security unit, EMCDDA

Dr Ana GALLEGOS

Head of Sector, Action on new drugs sector, Risks to public safety and security unit

Invited experts

Professor Dr Volker AUWÄRTER

Freiburg University, Institute of Forensic Medicine, Freiburg

Dr Robert KRONSTRAND

Dep. Forensic Genetics and Toxicology, Swedish National Board of Forensic Medicine, Linköping

Secretariat

Michael EVANS-BROWN

Programme manager — Risk assessment and risk communication, Action on new drugs sector, Risks to public safety and security unit, EMCDDA

EMCDDA

Alexis GOOSDEEL

Director

Dr Rachel CHRISTIE

Action on new drugs sector, Risks to public safety and security unit

Paulete DUQUE

Action on new drugs sector, Risks to public safety and security unit

Dr Rita JORGE

Action on new drugs sector, Risks to public safety and security unit

Joanna de MORAIS

Action on new drugs sector, Risks to public safety and security unit

Dr Gregorio PLANCHUELO

Action on new drugs sector, Risks to public safety and security unit

Maria MOREIRA

Scientific coordination unit

Recommended citation:

European Monitoring Centre for Drugs and Drug Addiction (2021), *Risk assessment report on the new psychoactive substance methyl 2-[[1-(4-fluorobutyl)-1H-indole-3-carbonyl]amino]-3,3-dimethylbutanoate (4F-MDMB-BICA) in accordance with Article 5c of Regulation (EC) No 1920/2006 (as amended)*, Risk Assessments, Publications Office of the European Union, Luxembourg.

About the EMCDDA

The European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) is the central source and confirmed authority on drug-related issues in Europe. For over 25 years, it has been collecting, analysing and disseminating scientifically sound information on drugs and drug addiction and their consequences, providing its audiences with an evidence-based picture of the drug phenomenon at European level.

The EMCDDA's publications are a prime source of information for a wide range of audiences including: policymakers and their advisors; professionals and researchers working in the drugs field; and, more broadly, the media and general public. Based in Lisbon, the EMCDDA is one of the decentralised agencies of the European Union.

Related publications and websites

- | [EMCDDA initial report on the new psychoactive substance 4F-MDBM-BICA, 2020](#)
- | [EMCDDA operating guidelines for the risk assessment of new psychoactive substances, 2020](#)
- | [EMCDDA operating guidelines for the European Union Early Warning System on new psychoactive substances, 2019](#)

These and all other EMCDDA publications are available from emcdda.europa.eu/publications

- | [EMCDDA Early Warning System on NPS](#)
- | [EMCDDA Risk assessment of NPS](#)
- | [EMCDDA New psychoactive substances webpage](#)

Legal notice: Neither the EMCDDA nor any person acting on behalf of the EMCDDA is responsible for the use that might be made of the following information.

Luxembourg: Publications Office of the European Union, 2022
doi:10.2810/398973 | ISBN 978-92-9497-701-4

© European Monitoring Centre for Drugs and Drug Addiction, 2022
Reproduction is authorised provided the source is acknowledged.
This publication is only available in electronic format.

EMCDDA, Praça Europa 1, Cais do Sodré, 1249-289 Lisbon, Portugal
Tel. (351) 211 21 02 00 | info@emcdda.europa.eu
emcdda.europa.eu | twitter.com/emcdda | facebook.com/emcdda